==== Front Evid Based Complement Alternat Med Evid Based Complement Alternat Med ECAM Evidence-based Complementary and Alternative Medicine : eCAM 1741-427X 1741-4288 Hindawi 10.1155/2020/6628641 Research Article An Investigation of the Molecular Mechanisms Underlying the Analgesic Effect of Jakyak-Gamcho Decoction: A Network Pharmacology Study Lee Ho-Sung 1 2 Lee In-Hee 1 Kang Kyungrae 2 Park Sang-In 3 Kwon Tae-Wook 2 https://orcid.org/0000-0002-3198-9881Lee Dae-Yeon foresthrnd@gmail.com 1 2 1The Fore, 87 Ogeum-ro, Songpa-gu, Seoul 05542, Republic of Korea 2Forest Hospital, 129 Ogeum-ro, Songpa-gu, Seoul 05549, Republic of Korea 3Forestheal Hospital, 173 Ogeum-ro, Songpa-gu, Seoul 05641, Republic of Korea Academic Editor: Xia Wang 2020 1 12 2020 1 12 2020 2020 66286419 10 2020 5 11 2020 24 11 2020 Copyright © 2020 Ho-Sung Lee et al.2020This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Herbal drugs have drawn substantial interest as effective analgesic agents; however, their therapeutic mechanisms remain to be fully understood. To address this question, we performed a network pharmacology study to explore the system-level mechanisms that underlie the analgesic activity of Jakyak-Gamcho decoction (JGd; Shaoyao-Gancao-Tang in Chinese and Shakuyaku-Kanzo-To in Japanese), an herbal prescription consisting of Paeonia lactiflora Pallas and Glycyrrhiza uralensis Fischer. Based on comprehensive information regarding the pharmacological and chemical properties of the herbal constituents of JGd, we identified 57 active chemical compounds and their 70 pain-associated targets. The JGd targets were determined to be involved in the regulation of diverse biological activities as follows: calcium- and cytokine-mediated signalings, calcium ion concentration and homeostasis, cellular behaviors of muscle and neuronal cells, inflammatory response, and response to chemical, cytokine, drug, and oxidative stress. The targets were further enriched in various pain-associated signalings, including the PI3K-Akt, estrogen, ErbB, neurotrophin, neuroactive ligand-receptor interaction, HIF-1, serotonergic synapse, JAK-STAT, and cAMP pathways. Thus, these data provide a systematic basis to understand the molecular mechanisms underlying the analgesic activity of herbal drugs. ==== Body 1. Introduction Pain is a major healthcare and socioeconomic issue worldwide that severely affects the overall health, quality of life, daily activities, and productivity of patients, and it places a substantial financial burden on healthcare systems and society [1–6]. Based on the pathophysiological mechanisms, pain is classified into (i) nociceptive and (ii) nonnociceptive neuropathic pain [7–21]. Nociceptive pain is caused by the activation and stimulation of nociceptors and pain pathways driven by inflammation, chemicals, or physical events, and it is subdivided into somatic and visceral [7–21]. Neuropathic pain develops due to damage, injury, dysfunction, or disease of the somatosensory nervous system, and it is further classified into central and peripheral [7–21]. At present, opioid analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and non-anti-inflammatory antipyretic analgesic agents serve as primary therapies for pain alleviation [6, 15, 22–28]. However, current treatment options for pain management are still associated with limited efficacy and unwanted adverse effects [6, 15, 22–28]. Meanwhile, herbal drugs and multicomponent-multitarget-multipathway polypharmacological therapeutics have received considerable attention for pain treatment because of their important analgesic effects with fewer side effects and toxicity [29–36]. Jakyak-Gamcho decoction (JGd; Shaoyao-Gancao-Tang in Chinese and Shakuyaku-Kanzo-To in Japanese) is an herbal drug that consists of Paeonia lactiflora Pallas and Glycyrrhiza uralensis Fischer, which has been prescribed for the treatment of various types of pain, gynecological diseases, arthritic diseases (e.g., osteoarthritis and arthralgia), and muscular diseases (myalgia, muscle tension, spasm, and cramps) [30, 37–48]. Previous studies have demonstrated the various therapeutic properties of JGd, including its analgesic, anti-inflammatory, antispasmodic, and antiallergic effects [30, 37–40, 43, 44, 46–55]. Among the diverse effects of this herbal drug, the most common therapeutic use of JGd is to alleviate pain arising from cancer, diabetes, neuropathy, and muscle and arthritis diseases [30, 37–40, 44, 46–48], which makes it one of the most frequently prescribed oral analgesic agents in East Asia [56]. The analgesic mechanisms of JGd include the modulation of spinal α2-adrenoceptors, transient receptor potential vanilloid 1 (TRPV1) channels, calcium and Sirt1 signalings, muscle contraction and relaxation, and chemokine and cytokine expression [39, 44, 46, 51, 57–60]. However, the pharmacological properties of JGd at the systemic level need to be explored. Because of the complex pharmacological nature of multicompound-multitarget-multipathway agents, there is often a fundamental limitation in investigating their comprehensive mechanisms of action based only on conventional biological experimental methodologies [61–68]. To overcome such challenges, network pharmacology, an integrative research field that systematically combines computational systems biology, network science, medicine, pharmacology, mathematics, and physics, has emerged as one of the most effective approaches for the mechanistic exploration of polypharmacological drugs, such as herbal medicines [61–68]. The goal of this integrative science is to unveil the mechanisms of disease pathogenesis and drug activity that are coordinated through the interactions among diverse biological components such as genes, proteins, cells, tissues, and organs [61–68]. Previous network pharmacology studies successfully investigated the polypharmacological properties of herbal drugs by identifying their active compounds and key therapeutic targets and further elucidating the distinct system-level pharmacological effects and mechanisms (e.g., therapeutic modulation of biological processes such as proliferation, apoptosis, cell cycle regulation, angiogenesis, oxidation and reduction, insulin metabolism, and inflammation) for the treatment of various diseases, including cancer, diabetes, arthritis, and ischemic stroke, which are exerted by the synergistic interplay between multiple compounds and targets contained in herbal drugs [61–79]. In the present network pharmacology study, we aimed to uncover the molecular mechanisms that underlie the analgesic properties of JGd with a system's perspective. 2. Materials and Methods 2.1. Screening of Active Chemical Compounds in Jakyak-Gamcho Decoction Information on chemical compounds comprising the herbal constituents of JGd was investigated using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database [80]. Then, based on their absorption, distribution, metabolism, and excretion (ADME) properties (i.e., oral bioavailability (OB), Caco-2 permeability, and drug-likeness (DL)), chemical compounds that satisfy the following criteria were screened and determined to be bioactive as previously suggested [63, 80, 81] using the TCMSP [80]: OB ≥ 30%, Caco-2 permeability ≥ -0.4, and DL ≥ 0.18. In brief, OB is the proportion of orally administered drug compounds that enter the general circulation, and it is one of the most crucial considerations in the design and development of a drug [80, 82]. Of note, compounds with an OB larger than 30% are commonly regarded as effectively absorbed in the human body [80, 82]. Caco-2 permeability is an important index for the investigation of intestinal permeability and drug efflux that is based on an evaluation of the rate of absorption and diffusion of a compound across Caco-2 human intestinal cells [80, 83–85]. In general, a chemical compound is considered not permeable in the intestinal epithelium if its Caco-2 permeability is lower than −0.4 [86, 87]. DL is a widely used measurement that qualitatively assesses whether a certain compound is physicochemically and structurally suitable for use as a drug [80, 88]. Note that the average DL of all drugs is 0.18, and therefore, it is commonly used as the threshold to determine the pharmacological potential of a compound [80, 88]. 2.2. Target Identification Human targets of the active chemical compounds of JGd were investigated using various databases and models, including the PharmMapper [89], search tool for interactions of chemicals (STITCH) 5 [90], Swiss Target Prediction [91], similarity ensemble approach (SEA) [92], systematic drug targeting tool (SysDT) [93], and weighted ensemble similarity (WES) [94]. The pain-associated human genes and proteins were investigated from the DisGeNET [95], Therapeutic Target Database [96], GeneCards [97], Comparative Toxicogenomics Database [98], Human Genome Epidemiology Navigator [99], Online Mendelian Inheritance in Man [100], Pharmacogenomics Knowledgebase [101], and DrugBank [102], using the medical subject headings term “Pain” (ID: D010146) for Homo sapiens species. 2.3. Network Construction The herbal medicine-active chemical compound (H-C), active chemical compound-target (C-T), and target-pathway (T-P) networks were generated by connecting the herbal medicines with their active chemical compounds, the compounds with their targets, and the targets with the signaling pathways in which they are enriched. The protein-protein interaction (PPI) network was generated using the STRING database (interaction confidence score ≥ 0.9) [103]. Analysis and visualization of networks were performed with Cytoscape software [104]. A network is composed of nodes (e.g., herbal medicines, chemical compounds, targets, or pathways) and edges (or links) describing the interactions among the nodes [105]. The degree is defined as the number of links of a node [105]. 2.4. Contribution Index Evaluation The network-based efficacy-based contribution index (CI) of active chemical compounds of JGd was evaluated following previous procedures as follows [81]: (1) NEj=∑i=1ndi,CIj=cj×NEj∑i=1mci×NEi×100%, where m is the number of chemical compounds, n is the number of targets of chemical compound j, di is the number of links of target i of chemical compound j, and ci (or cj) is the number of previous studies having “pain” and component i (or j) in their title or abstract searched from the PubMed database (https://pubmed.ncbi.nlm.nih.gov/). The chemical compounds with the highest CIs were regarded as contributing more to the pharmacological activity of a certain herbal drug [81]. 2.5. Functional Enrichment Analysis Gene ontology (GO) enrichment analysis was performed with g:Profiler [106]. Pathway enrichment analysis was performed with Kyoto Encyclopedia of Genes and Genomes database [107]. Functional association analysis was conducted using GeneMANIA [108]. 2.6. Molecular Docking Analysis The structures of chemical compounds of JGd and their targets were obtained from the PubChem [109] and RCSB Protein Databank [110] databases, respectively. Then, the molecular docking scores between the chemical compounds and the targets were assessed using AutoDock Vina [111]. Of note, a certain chemical compound is regarded as having high binding affinity to a target if the corresponding docking score is less than or equal to −5.0 [112, 113]. 3. Results The network pharmacology study for the exploration of analgesic mechanisms of JGd was conducted as follows (Figure 1). Detailed information regarding the chemical constituents of JGd was obtained from the comprehensive biomolecular databases, and the bioactive compounds were investigated using their ADME characteristics (Figure 1). The human targets of the active chemical compounds were identified from various databases and models that assess chemical-protein interactions (Figure 1). Then, we integrated the extensive herbal drug-related data into networks and performed network pharmacology analysis (Figure 1). 3.1. Active Chemical Compounds of Jakyak-Gamcho Decoction Detailed information regarding the chemical compounds present in JGd was obtained from TCMSP [80] (Supplementary Table S1), and the active compounds were defined as those with OB ≥ 30%, Caco-2 permeability ≥ −0.4, and DL ≥ 0.18, as described previously [63, 80, 81]. Some components were also determined to be active because of the substantial amount contained in JGd and their reported relevant pharmacological activity [42, 57, 114–128], although they did not meet the criteria. As a result, 111 active chemical compounds were obtained for JGd (Supplementary Table S2). 3.2. Targets of Jakyak-Gamcho Decoction We identified the targets of the active chemical compounds of JGd using the following databases and models for the investigation of chemical-protein interactions: Swiss Target Prediction [91], STITCH 5 [90], PharmMapper [89], SEA [92], SysDT [93], and WES [94]. Therefore, 70 human pain-associated and 137 nonpain-associated targets were obtained for JGd (Supplementary Table S3). 3.3. Network Pharmacology-Based Analysis of Jakyak-Gamcho Decoction To perform network pharmacology-based analysis of the pharmacological features of JGd, we constructed an herbal medicine-active chemical compound-target (H-C-T) network composed of 129 nodes (two herbal medicines, 57 active chemical compounds, and 70 pain-associated targets) and 217 links (Figure 2 and Supplementary Table S3) using comprehensive information regarding the herbal drug. We found that quercetin (number of targets = 36) and kaempferol (number of targets = 11) have relatively many targets (Figure 2 and Supplementary Table S3), implying that they might be important active compounds for the therapeutic activity of JGd. In addition, 27 human genes/proteins were found to be targeted by two or more active chemical compounds of JGd (Figure 2), suggesting a polypharmacological mechanism. To investigate the biological interaction relationship between the JGd targets, we generated a PPI network (58 nodes and 174 links) comprising the targets (Figure 3). Next, we searched for hubs, specific nodes with a high degree in the network that are shown to have crucial biological functions and promising therapeutic potential [129, 130]. In the analysis, hubs were determined as nodes for which the degree was greater than or equal to twice the average node degree of the network [131, 132]. The results showed that PIK3R1 (degree = 25), HSP90AA1 (degree = 15), EGFR (degree = 14), AKT1 (degree = 13), LPAR1 (degree = 13), LPAR2 (degree = 13), and LPAR3 (degree = 13) were hubs (Figure 3), implying that they might be the key targets responsible for the analgesic activity of JGd. These hubs were shown to be involved in the regulation of pain-related processes and could function as potent targets to induce analgesic effects. The PIK3R1 gene was suggested to have the potential to function as a pain-related regulator according to the genetic interaction analysis [133], and its expression level might be associated with osteoarthritis pathogenesis [134]. Upregulation of the HSP90AA1 gene was observed in patients with fibromyalgia [135–137], and pharmacological inhibition of heat shock protein 90 (HSP90; encoded by HSP90AA1) was shown to alleviate monoarthritis-induced pain [138]. The activation of epidermal growth factor receptor (EGFR; encoded by EGFR) and AKT (encoded by AKT1) is associated with the development and enhancement of diverse types of pain, and their therapeutic modulation might be associated with analgesic properties [139–156]. Lysophosphatidic acid receptor 1 (encoded by LPAR1) activity is involved in pain behavior arising from bone cancer, inflammation, diabetes, and neuropathy, and its pharmacological or genetic ablation might reduce the pain response [157–165]. Lysophosphatidic acid receptor 3 (encoded by LPAR3) plays crucial roles in the development and maintenance of neuropathic pain, and its blockade exerts analgesic effects [163, 166, 167]. We further assessed the CIs of the active chemical compounds of JGd to assess their pharmacological contribution to the analgesic effect of the herbal drug as described earlier [81, 168]. As a result, quercetin was shown to have the highest CI (91.83%) (Supplementary Figure S1), which suggests that this chemical compound might be the primary contributor to the analgesic activity of JGd. Together, these data indicate the system-level pharmacological properties of the analgesic activity of JGd. 3.4. Functional Enrichment Investigation of Jakyak-Gamcho Decoction Networks To investigate the molecular mechanisms underlying the analgesic effect of JGd, we carried out GO enrichment analysis of the targets. As a result, the JGd targets were enriched in GO terms involved in the modulation of a variety of biological activities, such as calcium- and cytokine-mediated signalings, calcium ion concentration and homeostasis, cellular behaviors of muscle and neuronal cells, inflammatory response, and response to chemical, cytokine, drug, and oxidative stress (Supplementary Figure S2), which are in accordance with the previously reported molecular mechanisms of the herbal drug [40, 41, 44, 46, 49, 55, 58–60, 169–172]. In addition, GeneMANIA analysis indicated that the JGd targets might functionally interact via diverse mechanisms (Supplementary Figure S3), implying the similarity in their pharmacological roles. Because various signaling pathways were reported to be associated with the initiation, transmission, perception, and maintenance of pain [12, 14, 20, 144, 155, 173–186], we carried out pathway enrichment analysis. We found that the JGd targets were enriched in the following signalings: “PI3K-Akt signaling pathway,” “Neuroactive ligand-receptor interaction,” “Estrogen signaling pathway,” “cAMP signaling pathway,” “Chemokine signaling pathway,” “JAK-STAT signaling pathway,” “Neurotrophin signaling pathway,” “AMPK signaling pathway,” “Dopaminergic synapse,” “ErbB signaling pathway,” “HIF-1 signaling pathway,” “Insulin signaling pathway,” “mTOR signaling pathway,” “Serotonergic synapse,” “Adipocytokine signaling pathway,” “Drug metabolism - cytochrome P450,” “IL-17 signaling pathway,” “TNF signaling pathway,” “Arachidonic acid metabolism,” and “VEGF signaling pathway” (Figure 4 and Supplementary Figure S2). These signalings are well-known pain-regulating pathways and function as therapeutic targets of analgesic and pain-relieving drugs. The activities of adenosine monophosphate-activated kinase (AMPK), ErbB, mammalian target of rapamycin (mTOR), phosphoinositide 3-kinase (PI3K)-Akt, tumor necrosis factor (TNF), or vascular endothelial growth factor (VEGF) signaling pathways are involved with the development and maintenance processes of various types of pathological pain, and their functional modulation might relieve neuropathic, nociceptive, and bone cancer pain [144, 149, 150, 155, 156, 187–226]. Furthermore, the activity of PI3K-Akt and the adipocytokine pathway further correlates with the severity of neuropathic and inflammatory pain, and their targeting agents exert analgesic effects [227–229]. The estrogen pathway serves as a modulator of the processing and sensitivity of visceral and mechanical pain responses [230–235]. Previous studies have shown the involvement of cyclic adenosine monophosphate (cAMP), chemokine, Janus kinase- (JAK-) signal transducer and activator of transcription (STAT), neurotrophin, and hypoxia-inducible factor (HIF) pathways in the initiation and persistence of inflammatory, cancer, and neuropathic pain, as well as their role as pharmacological mediators of analgesic approaches [141, 224, 236–265]. The impaired regulation of insulin signaling might promote the development of and pain sensation with diabetic neuropathy, which can be alleviated by its functional restoration [266–269]. The interleukin- (IL-) 17 pathway plays a crucial role in cellular mechanisms of pain pathogenesis and maintenance in various diseases including multiple sclerosis, prostatitis, intervertebral disk degeneration, femoral head osteonecrosis, and neuropathy; its inhibition might block the generation and persistence of pain [270–282]. Arachidonic acid metabolism is associated with the generation and secretion of diverse biomolecular substances responsible for the induction of inflammation and pain, and it is mainly involved in the mechanisms of action of NSAIDs [283–288]. Moreover, the serotonergic and dopaminergic synapse pathways are key neurotransmitters responsible for modulating the intensity and duration of pain, and their therapeutic interventions have been shown to attenuate pain behaviors [289–292]. Collectively, these results demonstrate the molecular- and pathway-level mechanisms underlying the analgesic activity of JGd. 3.5. Molecular Docking Evaluation To investigate the binding potential of the chemical compounds of JGd components for the targets, we evaluated their molecular docking activity. As a result, 95.09% of the binding interactions between the active chemical components of JGd and the hub targets was found to have docking scores equal to or lower than −5.0 (Figure 5 and Supplementary Table S4), indicating their therapeutic binding potential. Of note, the protein structures for LPAR2 and LPAR3 were unavailable in the RCSB Protein Databank [110]; therefore, they were excluded from the analysis. 4. Discussion Herbal medicines are increasingly being acknowledged as effective analgesic and pain-relieving agents owing to their promising therapeutic activity with fewer side effects [29–36]. JGd is a well-known herbal drug that alleviates pain induced by multiple diseases such as peripheral neuropathy, myalgia, arthralgia, and diabetes [30, 37–40, 44, 46–48], and it is one of the most frequently prescribed oral analgesics in East Asia [56]. Previous studies have attempted network pharmacology analyses to investigate the mechanisms underlying JGd for the treatment of osteoarthritis and Parkinson's disease [293, 294]; however, its network-perspective analgesic properties have not been fully elucidated. Therefore, this network pharmacology study attempted to investigate system-level mechanisms that underlie the analgesic activity of JGd. The ADME evaluation and network pharmacology investigation identified 57 active chemical compounds in JGd and their 70 pain-associated human molecular targets. Further enrichment analysis indicated that JGd targets were enriched with GO terms related to the modulation of biological activities, involving calcium- and cytokine-mediated signalings, calcium ion concentration and homeostasis, cellular behaviors of muscle and neuronal cells, inflammatory response, and response to chemical, cytokine, drug, and oxidative stress, consistent with the previously reported molecular mechanisms of the herbal drug [40, 41, 44, 46, 49, 55, 58–60, 169–172]. We further showed that JGd might target various pain signalings to exert its analgesic and pain-relieving effects, which involve the PI3K-Akt, estrogen, ErbB, neurotrophin, neuroactive ligand-receptor interaction, HIF-1, serotonergic synapse, JAK-STAT, and cAMP pathways. The analgesic activity of the chemical components of JGd has been previously reported. (+)-Catechin and pinocembrin produce analgesic, antineuropathy, and antinociceptive effects [295–297]. Albiflorin might play a pharmacological role as an analgesic, antineuropathy, and antinociceptive compound that can reduce pain intensity via the functional modulation of calcium channels, mitogen-activated protein kinase (MAPK) pathways, and various cytokines and chemokines [127, 298]. Moreover, formononetin, glabridin, glycyrrhizin, and paeonol exhibit anti-inflammatory, antinociceptive, and analgesic activities by inhibiting the generation of inflammatory cytokines and signaling molecules, thereby attenuating the pain responses [117, 120, 299–302]. Gallic acid could also have potential anti-inflammatory, antioxidant, and neuroprotective effects that could improve neuropathic pain, neuronal damage, and injury [119, 303, 304]. Glycyrrhizin and naringenin reduce inflammatory and neuropathic pain-like behaviors by modulating the secretion of inflammation-associated cytokines and mediators, as well as the activities of cyclic guanosine monophosphate (cGMP) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signalings [120, 301, 305–314]. Isoliquiritigenin was reported to possess analgesic, antispasmodic, and relaxant properties [315, 316]. Isorhamnetin ameliorates the pain intensity of diabetic neuropathy via its neuroprotective, antioxidative, and anti-inflammatory effects [317]. Kaempferol shows anti-inflammatory, antioxidant, and analgesic effects, which relieve the pain symptoms of gastritis, pancreatitis, and diabetic neuropathy [318–320]. In addition, liquiritigenin might suppress neuropathic pain by improving thermal, cold, and mechanical hyperalgesia [116]. Mairin (betulinic acid) has been shown to exert anti-inflammatory, antinociceptive, antipyretic, and analgesic effects, thereby alleviating visceral pain and chemotherapy-, infection-, and diabetes-associated neuropathies [321–326]. Quercetin reduces pain arising from inflammation, cancer, chronic prostatitis/chronic pelvic pain syndrome, arthritis, and muscle injury by inhibiting the induction of oxidative stress and activating inflammatory and adrenergic pathways, neurotransmitters, and cytokines [327–334]. In addition, quercetin further modulates the activity of a variety of pathways, including Toll-like receptor, mTOR, protein kinase Cε (PKCε)-TRPV1, p70 ribosomal S6 kinase (p70S6K), and P2X4 receptor signalings, as well as oxidative stress- and inflammation-associated mediators to exert its analgesic effects against diverse types of neuropathic pain [214, 335–347]. β-Sitosterol shows analgesic, antinociceptive, and anti-inflammatory activities [348–353]. These studies regarding the chemical components of JGd provide the pharmacological basis for the analgesic activities of this herbal drug. Based on the network pharmacological analyses, the following studies would contribute to the improvement of herbal drug therapies: (i) an assessment of the therapeutic efficacy of JGd analgesic activity in specific diseases that are associated with distinct types of pain, such as cancer, osteoarthritis, myalgia, arthralgia, and diabetes; (ii) a comprehensive exploration of the system-level mechanisms of analgesic properties of the herbal drug from diverse pharmacological perspectives, involving antinociceptive, anti-inflammatory, muscle relaxant, and antipyretic effects; and (iii) an investigation of the safety and effectiveness of combined treatment with JGd and widely used analgesic agents, including celecoxib, tramadol, and acetaminophen [24, 56, 354]. To conclude, we investigated the systems' perspective pharmacological properties of JGd, a widely prescribed analgesic herbal drug [56]. Based on the network pharmacological approach, we investigated 57 active chemical compounds and their 70 pain-related targets responsible for the analgesic activity of JGd. The targets of JGd were associated with the modulation of biological functions such as calcium- and cytokine-mediated signalings, calcium ion concentration and homeostasis, cellular behaviors of muscle and neuronal cells, inflammatory response, and response to chemical, cytokine, drug, and oxidative stress, which suggests the molecular mechanisms of JGd treatment. In addition, the enrichment analysis indicated that the targets are involved in various pathways that are associated with the pathophysiology of pain, including the PI3K-Akt, estrogen, ErbB, neurotrophin, neuroactive ligand-receptor interaction, HIF-1, serotonergic synapse, JAK-STAT, and cAMP pathways. The overall data offer a novel systematic view of the polypharmacological characteristics of herbal drugs and a mechanistic basis for their clinical implications for pain treatment. Data Availability The data used to support the findings of this study are included within the article and supplementary materials file. Conflicts of Interest The authors declare that there are no conflicts of interest. Supplementary Materials Supplementary Materials Supplementary Figure S1: contribution index analysis for the analgesic activity of active chemical compounds of Jakyak-Gamcho decoction. Supplementary Figure S2: functional enrichment analyses for the pain-associated targets of Jakyak-Gamcho decoction. Supplementary Figure S3: functional interaction analysis of the pain-associated targets of Jakyak-Gamcho decoction. Supplementary Table S1: list of the chemical compounds contained in Jakyak-Gamcho decoction. Supplementary Table S2: list of the active chemical compounds contained in Jakyak-Gamcho decoction. Supplementary Table S3: list of the targets of active chemical compounds of Jakyak-Gamcho decoction. Supplementary Table S4: docking scores of the active chemical compounds of Jakyak-Gamcho decoction with the hub targets. Click here for additional data file. Figure 1 A schematic diagram illustrating the network pharmacology exploration of the analgesic mechanisms of Jakyak-Gamcho decoction. Figure 2 The herbal medicine-active chemical compound-target network of Jakyak-Gamcho decoction. Green nodes, herbal medicines; red nodes, active chemical compounds; blue nodes, pain-related targets. Figure 3 The protein-protein interaction network for the pain-related targets of Jakyak-Gamcho decoction. Blue nodes, pain-related targets. Figure 4 The herbal medicine-active chemical compound-target-pathway network of Jakyak-Gamcho decoction. Green nodes, herbal medicines; red nodes, active chemical compounds; blue nodes, pain-related targets; orange nodes, signaling pathways. Figure 5 Molecular docking analysis of interactions between the active chemical compounds of Jakyak-Gamcho decoction and hub targets. (a) Calycosin-AKT1 (score = −7.5). (b) Gancaonin O-AKT1 (score = −5.7). (c) Quercetin-AKT1 (score = −6.4). (d) Quercetin-EGFR (score = −8.0). (e) Xambioona-EGFR (score = −10.5). (f) Glabridin-HSP90AA1 (score = −8.3). (g) Xambioona-HSP90AA1 (score = −9.1). (h) Mairin-LPAR1 (score = −8.4). (i) Calycosin-PIK3R1 (score = −7.9). (j) Quercetin-PIK3R1 (score = −6.3). ==== Refs 1 Goudas L. C. Bloch R. Gialeli-Goudas M. Lau J. Carr D. B. The epidemiology of cancer pain Cancer Investigation 2005 23 2 182 190 10.1081/cnv-50482 2-s2.0-16244385028 15813511 2 Macfarlane G. J. The epidemiology of chronic pain Pain 2016 157 10 2158 2159 10.1097/j.pain.0000000000000676 2-s2.0-84988939633 27643833 3 Russo M. M. Sundaramurthi T. An overview of cancer pain: epidemiology and pathophysiology Seminars in Oncology Nursing 2019 35 3 223 228 10.1016/j.soncn.2019.04.002 2-s2.0-85065404700 31085106 4 Smith B. H. Torrance N. Epidemiology of neuropathic pain and its impact on quality of life Current Pain and Headache Reports 2012 16 3 191 198 10.1007/s11916-012-0256-0 2-s2.0-84863394217 22395856 5 Stucky C. L. Gold M. S. Zhang X. Mechanisms of pain Proceedings of the National Academy of Sciences 2001 98 21 11845 11846 10.1073/pnas.211373398 2-s2.0-0035834013 6 Wolkerstorfer A. Handler N. Buschmann H. New approaches to treating pain Bioorganic & Medicinal Chemistry Letters 2016 26 4 1103 1119 10.1016/j.bmcl.2015.12.103 2-s2.0-84953455400 26774577 7 Butera J. A. Current and emerging targets to treat neuropathic pain Journal of Medicinal Chemistry 2007 50 11 2543 2546 10.1021/jm061015w 2-s2.0-34250218876 17489576 8 Chakravarty A. Sen A. Migraine, neuropathic pain and nociceptive pain: towards a unifying concept Medical Hypotheses 2010 74 2 225 231 10.1016/j.mehy.2009.08.034 2-s2.0-72449159573 19765908 9 Colloca L. Ludman T. Bouhassira D. Neuropathic pain Nature Reviews Disease Primers 2017 3 17002 10.1038/nrdp.2017.2 2-s2.0-85013188047 10 Epstein J. B. Wilkie D. J. Fischer D. J. Kim Y.-O. Villines D. Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy Head & Neck Oncology 2009 1 1 p. 26 10.1186/1758-3284-1-26 2-s2.0-76149137003 11 Freynhagen R. Parada H. A. Calderon-Ospina C. A. Current understanding of the mixed pain concept: a brief narrative review Current Medical Research and Opinion 2019 35 6 1011 1018 10.1080/03007995.2018.1552042 2-s2.0-85065131581 30479161 12 Hunt S. P. Mantyh P. W. The molecular dynamics of pain control Nature Reviews Neuroscience 2001 2 2 83 91 10.1038/35053509 2-s2.0-0035256911 11252998 13 Jehangir A. Abdallah R. T. Parkman H. P. Characterizing abdominal pain in patients with gastroparesis into neuropathic and nociceptive components Journal of Clinical Gastroenterology 2019 53 6 427 433 10.1097/mcg.0000000000001059 2-s2.0-85067354551 29782470 14 Jensen M. P. Day M. A. Miró J. Neuromodulatory treatments for chronic pain: efficacy and mechanisms Nature Reviews Neurology 2014 10 3 167 178 10.1038/nrneurol.2014.12 2-s2.0-84895926383 24535464 15 Mantyh P. W. Cancer pain and its impact on diagnosis, survival and quality of life Nature Reviews Neuroscience 2006 7 10 797 809 10.1038/nrn1914 2-s2.0-33748934201 16988655 16 Mantyh P. W. Clohisy D. R. Koltzenburg M. Hunt S. P. Molecular mechanisms of cancer pain Nature Reviews Cancer 2002 2 3 201 209 10.1038/nrc747 2-s2.0-0036515869 11990856 17 Morlion B. Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components Current Medical Research and Opinion 2011 27 1 11 33 10.1185/03007995.2010.534446 2-s2.0-78650373763 21083513 18 Nijs J. Leysen L. Adriaenssens N. Pain following cancer treatment: guidelines for the clinical classification of predominant neuropathic, nociceptive and central sensitization pain Acta Oncologica 2016 55 6 659 663 10.3109/0284186x.2016.1167958 2-s2.0-84965072211 27142228 19 Omoigui S. The biochemical origin of pain—proposing a new law of pain: the origin of all pain is inflammation and the inflammatory response. Part 1 of 3—a unifying law of pain Medical Hypotheses 2007 69 1 70 82 10.1016/j.mehy.2006.11.028 2-s2.0-34247609748 17240081 20 Thakur M. Dickenson A. H. Baron R. Osteoarthritis pain: nociceptive or neuropathic? Nature Reviews Rheumatology 2014 10 6 374 380 10.1038/nrrheum.2014.47 2-s2.0-84901950643 24686507 21 Yoon S. Y. Oh J. Neuropathic cancer pain: prevalence, pathophysiology, and management The Korean Journal of Internal Medicine 2018 33 6 1058 1069 10.3904/kjim.2018.162 2-s2.0-85056251156 29929349 22 Crofford L. J. Adverse effects of chronic opioid therapy for chronic musculoskeletal pain Nature Reviews Rheumatology 2010 6 4 191 197 10.1038/nrrheum.2010.24 2-s2.0-77950604262 20357788 23 Fine P. G. Analgesia issues in palliative care: bone pain, controlled release opioids, managing opioid-induced constipation and nifedipine as an analgesic Journal of Pain & Palliative Care Pharmacotherapy 2002 16 1 93 97 10.1080/j354v16n01_07 14650452 24 Kim S.-J. Seo J. T. Selection of analgesics for the management of acute and postoperative dental pain: a mini-review Journal of Periodontal & Implant Science 2020 50 2 68 73 10.5051/jpis.2020.50.2.68 32395385 25 Malfait A.-M. Schnitzer T. J. Towards a mechanism-based approach to pain management in osteoarthritis Nature Reviews Rheumatology 2013 9 11 654 664 10.1038/nrrheum.2013.138 2-s2.0-84887167582 24045707 26 Nelson A. D. Camilleri M. Opioid-induced constipation: advances and clinical guidance Therapeutic Advances in Chronic Disease 2016 7 2 121 134 10.1177/2040622315627801 2-s2.0-84959360356 26977281 27 Tolman K. G. Hepatotoxicity of non-narcotic analgesics The American Journal of Medicine 1998 105 1 13S 19S 10.1016/s0002-9343(98)00070-9 2-s2.0-0032572572 9715830 28 Yekkirala A. S. Roberson D. P. Bean B. P. Woolf C. J. Breaking barriers to novel analgesic drug development Nature Reviews Drug Discovery 2017 16 8 545 564 10.1038/nrd.2017.87 2-s2.0-85025454504 28596533 29 Chen L. Michalsen A. Management of chronic pain using complementary and integrative medicine BMJ 2017 357 j1284 10.1136/bmj.j1284 2-s2.0-85021857965 30 Hyodo T. Taira T. Takemura T. Immediate effect of shakuyaku-kanzo-to on muscle cramp in hemodialysis patients Nephron Clinical Practice 2006 104 1 c28 c32 10.1159/000093256 2-s2.0-33747273630 16685141 31 Kono T. Mamiya N. Chisato N. Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer Evid Based Complement Alternat Med 2011 2011 8 418481 10.1093/ecam/nep200 2-s2.0-79952239072 32 Luo Y. Wang C.-Z. Sawadogo R. Tan T. Yuan C.-S. Effects of herbal medicines on pain management The American Journal of Chinese Medicine 2020 48 1 1 16 10.1142/s0192415x20500019 32054304 33 Nishioka M. Shimada M. Kurita N. The kampo medicine, goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen International Journal of Clinical Oncology 2011 16 4 322 327 10.1007/s10147-010-0183-1 2-s2.0-80052738134 21258836 34 Tawata M. Kurihara A. Nitta K. Iwase E. Gan N. Onaya T. The effects of goshajinkigan, a herbal medicine, on subjective symptoms and vibratory threshold in patients with diabetic neuropathy Diabetes Research and Clinical Practice 1994 26 2 121 128 10.1016/0168-8227(94)90149-x 2-s2.0-0028558594 7705193 35 Yanju B. Yang L. Hua B. A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain Supportive Care in Cancer 2014 22 3 825 836 10.1007/s00520-013-2063-5 2-s2.0-84895858710 24276956 36 Yuan C.-S. Mehendale S. R. Wang C.-Z. Effects of Corydalis yanhusuo and Angelicae dahuricae on cold pressor-induced pain in humans: a controlled trial The Journal of Clinical Pharmacology 2004 44 11 1323 1327 10.1177/0091270004267809 2-s2.0-6344279952 15496650 37 Fujii K. Okamoto S. Saitoh K. The efficacy of shakuyaku-kanzo-to for peripheral nerve dysfunction in paclitaxel combination chemotherapy for epithelial ovarian carcinoma Gan To Kagaku Ryoho 2004 31 10 1537 1540 15508446 38 Fujiwara H. Urabe T. Ueda K. Prevention of arthralgia and myalgia from paclitaxel and carboplatin combination chemotherapy with shakuyaku-kanzo-to Gan To Kagaku Ryoho 2000 27 7 1061 1064 10925696 39 Hidaka T. Shima T. Nagira K. Herbal medicine shakuyaku-kanzo-to reduces paclitaxel-induced painful peripheral neuropathy in mice European Journal of Pain 2009 13 1 22 27 10.1016/j.ejpain.2008.03.003 2-s2.0-58149199933 18472288 40 Hinoshita F. Ogura Y. Suzuki Y. Effect of orally administered shao-yao-gan-cao-tang (shakuyaku-kanzo-to) on muscle cramps in maintenance hemodialysis patients: a preliminary study The American Journal of Chinese Medicine 2003 31 3 445 453 10.1142/s0192415x03001144 2-s2.0-20944444327 12943175 41 Lee K. K. Omiya Y. Yuzurihara M. Kase Y. Kobayashi H. Antispasmodic effect of shakuyakukanzoto extract on experimental muscle cramps in vivo: role of the active constituents of Glycyrrhizae radix Journal of Ethnopharmacology 2013 145 1 286 293 10.1016/j.jep.2012.11.005 2-s2.0-84871281530 23164761 42 Liu J. j. Cheng Y. Shao Y. y. Comparative pharmacokinetics and metabolites study of seven major bioactive components of shaoyao-gancao decoction in normal and polycystic ovary syndrome rats by ultra high pressure liquid chromatography with tandem mass spectrometry Journal of Separation Science 2019 42 15 2534 2549 10.1002/jssc.201900002 2-s2.0-85067338926 31144455 43 Shao Y. Y. Chang Z. P. Cheng Y. Shaoyao-Gancao decoction alleviated hyperandrogenism in a letrozole-induced rat model of polycystic ovary syndrome by inhibition of NF-κ B activation Bioscience Reports 2019 39 1 BSR20181877 10.1042/bsr20181877 2-s2.0-85059811484 44 Sui F. Zhou H.-Y. Meng J. A Chinese herbal decoction, shaoyao-gancao tang, exerts analgesic effect by down-regulating the TRPV1 channel in a rat model of arthritic pain The American Journal of Chinese Medicine 2016 44 7 1363 1378 10.1142/s0192415x16500762 2-s2.0-84994193554 27785943 45 Takahashi K. Kitao M. Effect of TJ-68 (shakuyaku-kanzo-to) on polycystic ovarian disease International Journal of Fertility and Menopausal Studies 1994 39 2 69 76 8012442 46 Tsuji S. Yasuda K. Sumi G. Shakuyaku-kanzo-to inhibits smooth muscle contractions of human pregnant uterine tissue in vitro Journal of Obstetrics and Gynaecology Research 2012 38 7 1004 1010 10.1111/j.1447-0756.2011.01827.x 2-s2.0-84864591480 47 Yamamoto K. Hoshiai H. Noda K. Effects of shakuyaku-kanzo-to on muscle pain from combination chemotherapy with paclitaxel and carboplatin Gynecologic Oncology 2001 81 2 333 334 10.1006/gyno.2001.6168 2-s2.0-0035018146 11330975 48 Yoshida T. Sawa T. Ishiguro T. Horiba A. Minatoguchi S. Fujiwara H. The efficacy of prophylactic shakuyaku-kanzo-to for myalgia and arthralgia following carboplatin and paclitaxel combination chemotherapy for non-small cell lung cancer Supportive Care in Cancer 2009 17 3 315 320 10.1007/s00520-008-0508-z 2-s2.0-59449098176 18839222 49 Chen I. C. Lin T. H. Hsieh Y. H. Formulated Chinese medicine shaoyao gancao tang reduces tau aggregation and exerts neuroprotection through anti-oxidation and anti-inflammation Oxid Med Cell Longev 2018 2018 16 9595741 10.1155/2018/9595741 2-s2.0-85060905575 50 Fujinami H. Kajiura S. Ando T. Mihara H. Hosokawa A. Sugiyama T. Direct spraying of shakuyakukanzoto onto the duodenal papilla: a novel method for preventing pancreatitis following endoscopic retrograde cholangiopancreatography Digestion 2015 91 1 42 45 10.1159/000368812 2-s2.0-84922324264 25632916 51 Kaifuchi N. Omiya Y. Kushida H. Fukutake M. Nishimura H. Kase Y. Effects of shakuyakukanzoto and its absorbed components on twitch contractions induced by physiological Ca2+ release in rat skeletal muscle Journal of Natural Medicines 2015 69 3 287 295 10.1007/s11418-015-0890-z 2-s2.0-84930763443 25783410 52 Sakai Y. Tsuyuguchi T. Ishihara T. Confirmation of the antispasmodic effect of shakuyaku-kanzo-to (TJ-68), a Chinese herbal medicine, on the duodenal wall by direct spraying during endoscopic retrograde cholangiopancreatography Journal of Natural Medicines 2009 63 2 200 203 10.1007/s11418-008-0304-6 2-s2.0-60849119253 19050990 53 Shen L. Cong W.-J. Lin X. Characterization using LC/MS of the absorption compounds and metabolites in rat plasma after oral administration of a single or mixed decoction of shaoyao and gancao Chemical and Pharmaceutical Bulletin 2012 60 6 712 721 10.1248/cpb.60.712 2-s2.0-84862325830 22689421 54 Shen L. Hu R.-w. Lin X. Pharmacokinetics of characteristic effective ingredients from individual and combination shaoyao and gancao treatement in rats using HPLC fingerprinting European Journal of Drug Metabolism and Pharmacokinetics 2012 37 2 133 140 10.1007/s13318-011-0052-y 2-s2.0-84863717519 21987053 55 Zhang Y. Jia X. Yang J. Effects of shaoyao-gancao decoction on infarcted cerebral cortical neurons: suppression of the inflammatory response following cerebral ischemia-reperfusion in a rat model BioMed Research International 2016 2016 14 1859254 10.1155/2016/1859254 2-s2.0-84978771902 56 Ushida T. Matsui D. Inoue T. Recent prescription status of oral analgesics in Japan in real-world clinical settings: retrospective study using a large-scale prescription database Expert Opinion on Pharmacotherapy 2019 20 16 2041 2052 10.1080/14656566.2019.1651840 2-s2.0-85070985475 31422709 57 Feng L.-M. Chen Y.-Y. Xu D.-Q. An integrated strategy for discovering effective components of shaoyao gancao decoction for treating neuropathic pain by the combination of partial least-squares regression and multi-index comprehensive method Journal of Ethnopharmacology 2020 260 113050 10.1016/j.jep.2020.113050 58 Omiya Y. Suzuki Y. Yuzurihara M. Antinociceptive effect of shakuyakukanzoto, a kampo medicine, in diabetic mice Journal of Pharmacological Sciences 2005 99 4 373 380 10.1254/jphs.fp0050536 2-s2.0-29144494143 16314688 59 Zhang J. Lv C. Wang H.-n. Cao Y. Synergistic interaction between total glucosides and total flavonoids on chronic constriction injury induced neuropathic pain in rats Pharmaceutical Biology 2013 51 4 455 462 10.3109/13880209.2012.739177 2-s2.0-84875161797 23336442 60 Zheng D. Zhang J. Wang R. Lu C. Guo X. Wang H. J. Administration of the influence of shaoyao gancao decoction extracts on IL-6 IL-1β and TNF-α in the chronic constriction injury rat model of neuropathic pain Chinese Archives of Traditional Chinese Medicine 2013 4 p. 36 61 Poornima P. Kumar J. D. Zhao Q. Blunder M. Efferth T. Network pharmacology of cancer: from understanding of complex interactomes to the design of multi-target specific therapeutics from nature Pharmacological Research 2016 111 290 302 10.1016/j.phrs.2016.06.018 2-s2.0-84976867169 27329331 62 Lee W. Y. Lee C. Y. Kim Y. S. Kim C. E. The methodological trends of traditional herbal medicine employing network pharmacology Biomolecules 2019 9 8 p. 362 10.3390/biom9080362 2-s2.0-85071280070 63 Lee H. S. Lee I. H. Park S. I. Lee D. Y. Network pharmacology-based investigation of the system-level molecular mechanisms of the hematopoietic activity of Samul-Tang, a traditional Korean herbal formula Evidence-Based Complementary and Alternative Medicine 2020 2020 17 9048089 10.1155/2020/9048089 64 He R. Ou S. Chen S. Ding S. Network pharmacology-based study on the molecular biological mechanism of action for compound kushen injection in anti-cancer effect Medical Science Monitor 2020 26 e918520 10.12659/msm.918520 65 Mi J. L. Liu C. Xu M. Wang R. S. Network pharmacology to uncover the molecular mechanisms of action of LeiGongTeng for the treatment of nasopharyngeal carcinoma Medical Science Monitor Basic Research 2020 26 e923431 10.12659/msmbr.923431 66 Wang Y. Dong B. Xue W. Anticancer effect of radix astragali on cholangiocarcinoma in vitro and its mechanism via network pharmacology Medical Science Monitor 2020 26 e921162 10.12659/msm.921162 67 Xu T. Wang Q. Liu M. A network pharmacology approach to explore the potential mechanisms of huangqin-baishao herb pair in treatment of cancer Medical Science Monitor 2020 26 e923199 10.12659/msm.923199 68 Zhang S. Q. Xu H. B. Zhang S. J. Li X. Y. Identification of the active compounds and significant pathways of Artemisia annua in the treatment of non-small cell lung carcinoma based on network pharmacology Medical Science Monitor 2020 26 e923624-1 e923624-11 10.12659/MSM.923624 32474568 69 Hu Z. Yang M. Yang L. Network pharmacology-based identification of the mechanisms of Shen-Qi compound formula in treating diabetes mellitus Evidence-Based Complementary and Alternative Medicine 2020 2020 15 5798764 10.1155/2020/5798764 70 Jiang Y. Zhong M. Long F. Yang R. Deciphering the active ingredients and molecular mechanisms of Tripterygium hypoglaucum (Levl.) hutch against rheumatoid arthritis based on network pharmacology Evidence-Based Complementary and Alternative Medicine 2020 2020 9 2361865 10.1155/2020/2361865 71 Li D. H. Su Y. F. Sun C. X. Fan H. F. Gao W. J. A network pharmacology-based identification study on the mechanism of Xiao-Xu-Ming decoction for cerebral ischemic stroke Evidence-Based Complementary and Alternative Medicine 2020 2020 8 2507074 10.1155/2020/2507074 72 Liu W. Fan Y. Tian C. Deciphering the molecular targets and mechanisms of HGWD in the treatment of rheumatoid arthritis via network pharmacology and molecular docking Evidence-Based Complementary and Alternative Medicine 2020 2020 13 7151634 10.1155/2020/7151634 73 Qian H. Jin Q. Liu Y. Study on the multitarget mechanism of sanmiao pill on gouty arthritis based on network pharmacology Evidence-Based Complementary and Alternative Medicine 2020 2020 11 9873739 10.1155/2020/9873739 74 Ren B. Tan L. Xiong Y. Integrated analysis of the mechanisms of Da-Chai-Hu decoction in type 2 diabetes mellitus by a network pharmacology approach Evidence-Based Complementary and Alternative Medicine 2020 2020 21 9768414 10.1155/2020/9768414 75 Wang W. Zhang Y. Luo J. Wang R. Tang C. Zhang Y. Virtual screening technique used to estimate the mechanism of Adhatoda vasica nees for the treatment of rheumatoid arthritis based on network pharmacology and molecular docking Evidence-Based Complementary and Alternative Medicine 2020 2020 12 5872980 10.1155/2020/5872980 76 Xiao K. Li K. Long S. Kong C. Zhu S. Potential molecular mechanisms of Chaihu-Shugan-San in treatment of breast cancer based on network pharmacology Evidence-Based Complementary and Alternative Medicine 2020 2020 9 3670309 10.1155/2020/3670309 77 Yang K. Zeng L. Ge J. Exploring the pharmacological mechanism of Danzhi Xiaoyao powder on ER-positive breast cancer by a network pharmacology approach Evidence-Based Complementary and Alternative Medicine 2018 2018 20 5059743 10.1155/2018/5059743 2-s2.0-85046258677 78 Zhang C. Liao Y. Liu L. A network pharmacology approach to investigate the active compounds and mechanisms of musk for ischemic stroke Evidence-Based Complementary and Alternative Medicine 2020 2020 14 4063180 10.1155/2020/4063180 79 Zhou J. Wang Q. Xiang Z. Network pharmacology analysis of traditional Chinese medicine formula Xiao Ke Yin Shui treating type 2 diabetes mellitus Evidence-Based Complementary and Alternative Medicine 2019 2019 15 4202563 10.1155/2019/4202563 2-s2.0-85072740634 80 Ru J. Li P. Wang J. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines Journal of Cheminformatics 2014 6 p. 13 10.1186/1758-2946-6-13 2-s2.0-84899981355 81 Yue S. J. Xin L. T. Fan Y. C. Herb pair Danggui-Honghua: mechanisms underlying blood stasis syndrome by system pharmacology approach Scientific Reports 2017 7 40318 10.1038/srep40318 2-s2.0-85009238129 82 Wang C. K. Craik D. J. Cyclic peptide oral bioavailability: lessons from the past Biopolymers 2016 106 6 901 909 10.1002/bip.22878 2-s2.0-84996534043 27178381 83 Kono Y. Iwasaki A. Matsuoka K. Fujita T. Effect of mechanical agitation on cationic liposome transport across an unstirred water layer in caco-2 cells Biological & Pharmaceutical Bulletin 2016 39 8 1293 1299 10.1248/bpb.b16-00050 2-s2.0-84979976432 27476939 84 Volpe D. A. Variability in caco-2 and MDCK cell-based intestinal permeability assays Journal of Pharmaceutical Sciences 2008 97 2 712 725 10.1002/jps.21010 2-s2.0-39749114622 17542022 85 Garcia M. N. Flowers C. Cook J. D. The caco-2 cell culture system can be used as a model to study food iron availability The Journal of Nutrition 1996 126 1 251 258 10.1093/jn/126.1.251 8558308 86 Li Y. Zhang J. Zhang L. Systems pharmacology to decipher the combinational anti-migraine effects of Tianshu formula Journal of Ethnopharmacology 2015 174 45 56 10.1016/j.jep.2015.07.043 2-s2.0-84939250444 26231449 87 Zhang J. Li Y. Chen X. Pan Y. Zhang S. Wang Y. Systems pharmacology dissection of multi-scale mechanisms of action for herbal medicines in stroke treatment and prevention PLoS One 2014 9 8 e102506 10.1371/journal.pone.0102506 2-s2.0-84905460204 88 Lee A. Y. Park W. Kang T.-W. Cha M. H. Chun J. M. Network pharmacology-based prediction of active compounds and molecular targets in Yijin-Tang acting on hyperlipidaemia and atherosclerosis Journal of Ethnopharmacology 2018 221 151 159 10.1016/j.jep.2018.04.027 2-s2.0-85046735121 29698773 89 Wang X. Shen Y. Wang S. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database Nucleic Acids Research 2017 45 W1 W356 W360 10.1093/nar/gkx374 2-s2.0-85023190745 28472422 90 Szklarczyk D. Santos A. von Mering C. Jensen L. J. Bork P. Kuhn M. Stitch 5: augmenting protein-chemical interaction networks with tissue and affinity data Nucleic Acids Research 2016 44 D1 D380 D384 10.1093/nar/gkv1277 2-s2.0-84976897983 26590256 91 Daina A. Michielin O. Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules Nucleic Acids Research 2019 47 W1 W357 W364 10.1093/nar/gkz382 2-s2.0-85069235505 31106366 92 Keiser M. J. Roth B. L. Armbruster B. N. Ernsberger P. Irwin J. J. Shoichet B. K. Relating protein pharmacology by ligand chemistry Nature Biotechnology 2007 25 2 197 206 10.1038/nbt1284 2-s2.0-33846876695 93 Yu H. Chen J. Xu X. A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data PLoS One 2012 7 5 e37608 10.1371/journal.pone.0037608 2-s2.0-84861610134 94 Zheng C. Guo Z. Huang C. Large-scale direct targeting for drug repositioning and discovery Scientific Reports 2015 5 11970 10.1038/srep11970 2-s2.0-84936972913 95 Piñero J. Bravo À. Queralt-Rosinach N. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants Nucleic Acids Research 2017 45 D1 D833 D839 10.1093/nar/gkw943 2-s2.0-85016126262 27924018 96 Zhu F. Han B. Kumar P. Update of TTD: therapeutic target database Nucleic Acids Research 2010 38 1 D787 D791 10.1093/nar/gkp1014 2-s2.0-75549090848 19933260 97 Safran M. Dalah I. Alexander J. GeneCards version 3: the human gene integrator Database 2010 2010 baq020 10.1093/database/baq020 2-s2.0-78049480691 98 Davis A. P. Grondin C. J. Johnson R. J. The comparative toxicogenomics database: update 2019 Nucleic Acids Research 2019 47 D1 D948 D954 10.1093/nar/gky868 2-s2.0-85059795504 30247620 99 Yu W. Gwinn M. Clyne M. Yesupriya A. Khoury M. J. A navigator for human genome epidemiology Nature Genetics 2008 40 2 124 125 10.1038/ng0208-124 2-s2.0-38649091333 18227866 100 Amberger J. S. Bocchini C. A. Schiettecatte F. Scott A. F. Hamosh A. OMIM.org: online Mendelian inheritance in man (OMIM®), an online catalog of human genes and genetic disorders Nucleic Acids Research 2015 43 D1 D789 D798 10.1093/nar/gku1205 2-s2.0-84946081339 25428349 101 Whirl-Carrillo M. McDonagh E. M. Hebert J. M. Pharmacogenomics knowledge for personalized medicine Clinical Pharmacology & Therapeutics 2012 92 4 414 417 10.1038/clpt.2012.96 2-s2.0-84866611528 22992668 102 Wishart D. S. Feunang Y. D. Guo A. C. DrugBank 5.0: a major update to the DrugBank database for 2018 Nucleic Acids Research 2018 46 D1 D1074 D1082 10.1093/nar/gkx1037 2-s2.0-85040924244 29126136 103 Szklarczyk D. Gable A. L. Lyon D. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets Nucleic Acids Research 2019 47 D1 D607 D613 10.1093/nar/gky1131 2-s2.0-85059797047 30476243 104 Shannon P. Markiel A. Ozier O. Cytoscape: a software environment for integrated models of biomolecular interaction networks Genome Research 2003 13 11 2498 2504 10.1101/gr.1239303 2-s2.0-0242490780 14597658 105 Barabási A.-L. Oltvai Z. N. Network biology: understanding the cell’s functional organization Nature Reviews Genetics 2004 5 2 101 113 10.1038/nrg1272 2-s2.0-0742305866 106 Raudvere U. Kolberg L. Kuzmin I. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update) Nucleic Acids Research 2019 47 W1 W191 W198 10.1093/nar/gkz369 2-s2.0-85068995138 31066453 107 Kanehisa M. Goto S. KEGG: kyoto encyclopedia of genes and genomes Nucleic Acids Research 2000 28 1 27 30 10.1093/nar/28.1.27 10592173 108 Montojo J. Zuberi K. Rodriguez H. Bader G. D. Morris Q. GeneMANIA: fast gene network construction and function prediction for Cytoscape F1000 Research 2014 3 p. 153 10.12688/f1000research.4572.1 2-s2.0-84908648308 109 Kim S. Chen J. Cheng T. PubChem 2019 update: improved access to chemical data Nucleic Acids Research 2019 47 D1 D1102 D1109 10.1093/nar/gky1033 2-s2.0-85057747380 30371825 110 Burley S. K. Berman H. M. Bhikadiya C. RCSB protein data bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy Nucleic Acids Research 2019 47 D1 D464 D474 10.1093/nar/gky1004 2-s2.0-85059796705 30357411 111 Trott O. Olson A. J. AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading Journal of Computational Chemistry 2010 31 2 455 461 10.1002/jcc.21334 2-s2.0-76149120388 19499576 112 Zhuang Z. Wen J. Zhang L. Can network pharmacology identify the anti-virus and anti- inflammatory activities of shuanghuanglian oral liquid used in Chinese medicine for respiratory tract infection? European Journal of Integrative Medicine 2020 37 101139 10.1016/j.eujim.2020.101139 113 Zhang M. Yuan Y. Zhou W. Network pharmacology analysis of Chaihu Lizhong Tang treating non-alcoholic fatty liver disease Computational Biology and Chemistry 2020 86 107248 10.1016/j.compbiolchem.2020.107248 114 Boisnic S. Ben Slama L. Branchet-Gumila M. C. Watts M. d’Arros G. Effet anti-inflammatoire de l’enoxolone dans un modèle ex-vivo de muqueuse gingivale humaine Revue de Stomatologie et de Chirurgie Maxillo-Faciale 2010 111 2 69 73 10.1016/j.stomax.2010.02.005 2-s2.0-77950689710 20338604 115 Chae H.-S. Kang O.-H. Lee Y.-S. Inhibition of LPS-induced iNOS, COX-2 and inflammatory mediator expression by paeonol through the MAPKs inactivation in RAW 264.7 cells The American Journal of Chinese Medicine 2009 37 1 181 194 10.1142/s0192415x0900676x 2-s2.0-65449182356 19222121 116 Chen L. Chen W. Qian X. Fang Y. Zhu N. Liquiritigenin alleviates mechanical and cold hyperalgesia in a rat neuropathic pain model Scientific Reports 2014 4 5676 10.1038/srep05676 2-s2.0-84904498133 117 Chou T.-C. Anti-inflammatory and analgesic effects of paeonol in carrageenan-evoked thermal hyperalgesia British Journal of Pharmacology 2003 139 6 1146 1152 10.1038/sj.bjp.0705360 2-s2.0-0041667974 12871833 118 Dong L. Yin L. Zhang Y. Fu X. Lu J. Anti-inflammatory effects of ononin on lipopolysaccharide-stimulated RAW 264.7 cells Molecular Immunology 2017 83 46 51 10.1016/j.molimm.2017.01.007 2-s2.0-85009193415 28095349 119 Kaur S. Muthuraman A. Ameliorative effect of gallic acid in paclitaxel-induced neuropathic pain in mice Toxicology Reports 2019 6 505 513 10.1016/j.toxrep.2019.06.001 2-s2.0-85067054075 31211096 120 Sun X. Zeng H. Wang Q. Glycyrrhizin ameliorates inflammatory pain by inhibiting microglial activation-mediated inflammatory response via blockage of the HMGB1-TLR4-NF-kB pathway Experimental Cell Research 2018 369 1 112 119 10.1016/j.yexcr.2018.05.012 2-s2.0-85047077208 29763588 121 Wang Y. Xu C. Wang P. Pharmacokinetic comparisons of different combinations of shaoyao-gancao-decoction in rats: simultaneous determination of ten active constituents by HPLC-MS/MS Journal of Chromatography B 2013 932 76 87 10.1016/j.jchromb.2013.06.021 2-s2.0-84880291540 122 Xu C.-H. Wang P. Wang Y. Pharmacokinetic comparisons of two different combinations of shaoyao-gancao decoction in rats: competing mechanisms between paeoniflorin and glycyrrhetinic acid Journal of Ethnopharmacology 2013 149 2 443 452 10.1016/j.jep.2013.06.049 2-s2.0-84883191146 23867078 123 Yerra V. G. Kalvala A. K. Kumar A. Isoliquiritigenin reduces oxidative damage and alleviates mitochondrial impairment by SIRT1 activation in experimental diabetic neuropathy The Journal of Nutritional Biochemistry 2017 47 41 52 10.1016/j.jnutbio.2017.05.001 2-s2.0-85019417749 28528294 124 Yu C. Zhang Y. Gao K.-X. Serotonergically dependent antihyperalgesic and antiallodynic effects of isoliquiritin in a mouse model of neuropathic pain European Journal of Pharmacology 2020 881 173184 10.1016/j.ejphar.2020.173184 125 Zhang L. Li D.-c. Liu L.-f. Paeonol: pharmacological effects and mechanisms of action International Immunopharmacology 2019 72 413 421 10.1016/j.intimp.2019.04.033 2-s2.0-85064702379 31030097 126 Zhang M.-T. Wang B. Jia Y.-N. Neuroprotective effect of liquiritin against neuropathic pain induced by chronic constriction injury of the sciatic nerve in mice Biomedicine & Pharmacotherapy 2017 95 186 198 10.1016/j.biopha.2017.07.167 2-s2.0-85027976681 28843150 127 Zhou J. Wang L. Wang J. Paeoniflorin and albiflorin attenuate neuropathic pain via MAPK pathway in chronic constriction injury rats Evidence-Based Complementary and Alternative Medicine 2016 2016 11 8082753 10.1155/2016/8082753 2-s2.0-84982836725 128 Kim S.-A. Jang E.-S. Lee A. Lee S.-J. Kim J.-H. Anti-inflammatory and anti-oxidant effects of oxypaeoniflorin, paeoniflorin and Paeonia lactiflora cv. “red charm” flower petal extracts in macrophage cells Korean Journal of Plant Resources 2020 33 3 153 162 129 Cho D. Y. Kim Y. A. Przytycka T. M. Chapter 5: network biology approach to complex diseases PLoS Computational Biology 2012 8 12 e1002820 10.1371/journal.pcbi.1002820 2-s2.0-84872037912 130 Jeong H. Mason S. P. Barabási A.-L. Oltvai Z. N. Lethality and centrality in protein networks Nature 2001 411 6833 41 42 10.1038/35075138 2-s2.0-0035799707 11333967 131 Zhu J. Yi X. Zhang Y. Pan Z. Zhong L. Huang P. Systems pharmacology-based approach to comparatively study the independent and synergistic mechanisms of danhong injection and naoxintong capsule in ischemic stroke treatment Evidence-Based Complementary and Alternative Medicine 2019 2019 17 1056708 10.1155/2019/1056708 2-s2.0-85062374336 132 Zhong J. Liu Z. Zhou X. Xu J. Synergic anti-pruritus mechanisms of action for the radix Sophorae flavescentis and fructus cnidii herbal pair Molecules 2017 22 9 1465 10.3390/molecules22091465 2-s2.0-85029654682 133 Perkins J. R. Lees J. Antunes-Martins A. PainNetworks: a web-based resource for the visualisation of pain-related genes in the context of their network associations Pain 2013 154 12 2586 e1 2586.e12 10.1016/j.pain.2013.09.003 2-s2.0-84889092648 24036287 134 Shi T. Shen X. Gao G. Gene expression profiles of peripheral blood monocytes in osteoarthritis and analysis of differentially expressed genes BioMed Research International 2019 2019 12 4291689 10.1155/2019/4291689 135 Lukkahatai N. Majors B. Reddy S. Walitt B. Saligan L. N. Gene expression profiles of fatigued fibromyalgia patients with different categories of pain and catastrophizing: a preliminary report Nursing Outlook 2013 61 4 216.e2 224.e2 10.1016/j.outlook.2013.03.007 2-s2.0-84880153954 23684314 136 Lukkahatai N. Walitt B. Espina A. Wang D. Saligan L. N. Comparing genomic profiles of women with and without fibromyalgia Biological Research For Nursing 2015 17 4 373 383 10.1177/1099800415589785 2-s2.0-84931402649 26015072 137 Vincent A. Benzo R. P. Whipple M. O. McAllister S. J. Erwin P. J. Saligan L. N. Beyond pain in fibromyalgia: insights into the symptom of fatigue Arthritis Research & Therapy 2013 15 6 p. 221 10.1186/ar4395 2-s2.0-84888794655 138 Nascimento D. S. M. Potes C. S. Soares M. L. Drug-induced HSP90 inhibition alleviates pain in monoarthritic rats and alters the expression of new putative pain players at the DRG Molecular Neurobiology 2018 55 5 3959 3975 10.1007/s12035-017-0628-x 2-s2.0-85019705564 28550532 139 Duan B. Liu D.-S. Huang Y. PI3-kinase/Akt pathway-regulated membrane insertion of acid-sensing ion channel 1a underlies BDNF-induced pain hypersensitivity Journal of Neuroscience 2012 32 18 6351 6363 10.1523/jneurosci.4479-11.2012 2-s2.0-84860351788 22553040 140 Guan X. Fu Q. Xiong B. Activation of PI3Kγ /Akt pathway mediates bone cancer pain in rats Journal of Neurochemistry 2015 134 3 590 600 10.1111/jnc.13139 2-s2.0-84935499529 25919859 141 Guan X.-H. Fu Q.-C. Shi D. Activation of spinal chemokine receptor CXCR3 mediates bone cancer pain through an Akt-ERK crosstalk pathway in rats Experimental Neurology 2015 263 39 49 10.1016/j.expneurol.2014.09.019 2-s2.0-84907964792 25281485 142 Guedes R. P. Araújo A. S. R. Janner D. Belló-Klein A. Ribeiro M. F. M. Partata W. A. Increase in reactive oxygen species and activation of Akt signaling pathway in neuropathic pain Cellular and Molecular Neurobiology 2008 28 8 1049 1056 10.1007/s10571-008-9279-9 2-s2.0-57449089013 18379870 143 Hu B. Xu G. Zhang X. Paeoniflorin attenuates inflammatory pain by inhibiting microglial activation and Akt-NF-κ b signaling in the central nervous system Cellular Physiology and Biochemistry 2018 47 2 842 850 10.1159/000490076 2-s2.0-85048959825 29807368 144 Jin D. Yang J.-p. Hu J.-h. Wang L.-n. Zuo J.-l. MCP-1 stimulates spinal microglia via PI3K/Akt pathway in bone cancer pain Brain Research 2015 1599 158 167 10.1016/j.brainres.2014.12.043 2-s2.0-84923383365 25555372 145 Kersten C. Cameron M. G. Cetuximab alleviates neuropathic pain despite tumour progression BMJ Case Reports 2012 2012 bcr1220115374 10.1136/bcr.12.2011.5374 2-s2.0-84864577556 146 Kersten C. Cameron M. G. Laird B. Mjåland S. Epidermal growth factor receptor—inhibition (EGFR-I) in the treatment of neuropathic pain British Journal of Anaesthesia 2015 115 5 761 767 10.1093/bja/aev326 2-s2.0-84946140144 26475804 147 Li D. Chen H. Luo X.-H. Sun Y. Xia W. Xiong Y.-C. CX3CR1-mediated Akt1 activation contributes to the paclitaxel-induced painful peripheral neuropathy in rats Neurochemical Research 2016 41 6 1305 1314 10.1007/s11064-016-1827-y 2-s2.0-84960107859 26961886 148 Li S.-S. Zhang W.-S. Yang J.-L. Xiong Y.-C. Zhang Y.-Q. Xu H. Involvement of protein kinase B/Akt in analgesic effect of dexmedetomidine on neuropathic pain CNS Neuroscience & Therapeutics 2013 19 5 364 366 10.1111/cns.12100 2-s2.0-84876797192 23607700 149 Li X. Yang S. Wang L. Resveratrol inhibits paclitaxel-induced neuropathic pain by the activation of PI3K/Akt and SIRT1/PGC1alpha pathway Journal of Pain Research 2019 12 879 890 10.2147/jpr.s185873 2-s2.0-85062982635 30881098 150 Liu W. Lv Y. Ren F. PI3K/Akt pathway is required for spinal central sensitization in neuropathic pain Cellular and Molecular Neurobiology 2018 38 3 747 755 10.1007/s10571-017-0541-x 2-s2.0-85028554590 28849293 151 Martin L. J. Smith S. B. Khoutorsky A. Epiregulin and EGFR interactions are involved in pain processing The Journal of Clinical Investigation 2017 127 9 3353 3366 10.1172/jci87406 2-s2.0-85028943267 28783046 152 Scheff N. N. Ye Y. Conley Z. R. A disintegrin and metalloproteinase domain 17-epidermal growth factor receptor signaling contributes to oral cancer pain Pain 2020 161 10 2330 2343 10.1097/j.pain.0000000000001926 32453136 153 Sun R. Yan J. Willis W. D. Activation of protein kinase B/Akt in the periphery contributes to pain behavior induced by capsaicin in rats Neuroscience 2007 144 1 286 294 10.1016/j.neuroscience.2006.08.084 2-s2.0-33751549452 17084039 154 Wang S. Liu S. Xu L. The upregulation of EGFR in the dorsal root ganglion contributes to chronic compression of dorsal root ganglions-induced neuropathic pain in rats Molecular Pain 2019 15 1744806919857297 10.1177/1744806919857297 2-s2.0-85067600520 155 Yan Y. Liang Y. Ding T. Chu H. PI3K/Akt signaling pathway may be involved in MCP-1-induced P2X4R expression in cultured microglia and cancer-induced bone pain rats Neuroscience Letters 2019 701 100 105 10.1016/j.neulet.2019.02.024 2-s2.0-85061959113 30776493 156 Zhang W. Suo M. Yu G. Zhang M. Antinociceptive and anti-inflammatory effects of cryptotanshinone through PI3K/Akt signaling pathway in a rat model of neuropathic pain Chem Biol Interact 2019 305 127 133 10.1016/j.cbi.2019.03.016 2-s2.0-85063778316 30922766 157 Han M. M. Yang C. W. Cheung C. W. Li J. Blockage of spinal endothelin A receptors attenuates bone cancer pain via regulation of the Akt/ERK signaling pathway in mice Neuropeptides 2018 68 36 42 10.1016/j.npep.2018.01.003 2-s2.0-85040990130 29395120 158 Rivera R. R. Lin M. E. Bornhop E. C. Chun J. Conditional Lpar1 gene targeting identifies cell types mediating neuropathic pain Federation of American Societies for Experimental Biology Journal 2020 34 7 8833 8842 10.1096/fj.202000317r 32929779 159 Srikanth M. Chew W. S. Hind T. Lysophosphatidic acid and its receptor LPA1 mediate carrageenan induced inflammatory pain in mice European Journal of Pharmacology 2018 841 49 56 10.1016/j.ejphar.2018.10.005 2-s2.0-85055188086 30321532 160 Uchida H. Nagai J. Ueda H. Lysophosphatidic acid and its receptors LPA1 and LPA3 mediate paclitaxel-induced neuropathic pain in mice Molecular Pain 2014 10 p. 71 10.1186/1744-8069-10-71 2-s2.0-84925282924 161 Ueda H. Neyama H. LPA1 receptor involvement in fibromyalgia-like pain induced by intermittent psychological stress, empathy Neurobiology of Pain 2017 1 16 25 10.1016/j.ynpai.2017.04.002 2-s2.0-85029878580 31194005 162 Ueda H. Neyama H. Matsushita Y. Lysophosphatidic acid receptor 1- and 3-mediated hyperalgesia and hypoalgesia in diabetic neuropathic pain models in mice Cells 2020 9 8 1906 10.3390/cells9081906 163 Ueda H. Neyama H. Sasaki K. Miyama C. Iwamoto R. Lysophosphatidic acid LPA1 and LPA3 receptors play roles in the maintenance of late tissue plasminogen activator-induced central poststroke pain in mice Neurobiol Pain 2019 5 100020 10.1016/j.ynpai.2018.07.001 2-s2.0-85064096412 164 Wu J. X. Yuan X. M. Wang Q. Wei W. Xu M. Y. Rho/ROCK acts downstream of lysophosphatidic acid receptor 1 in modulating P2X3 receptor-mediated bone cancer pain in rats Molecular Pain 2016 12 1744806916644929 10.1177/1744806916644929 2-s2.0-84988568542 165 Wu X. P. Yang Y. P. She R. X. Xing Z. M. Chen H. W. Zhang Y. W. microRNA-329 reduces bone cancer pain through the LPAR1-dependent LPAR1/ERK signal transduction pathway in mice Therapeutic Advances in Medical Oncology 2019 11 1758835919875319 10.1177/1758835919875319 2-s2.0-85074163188 166 Ma L. Uchida H. Nagai J. Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain Molecular Pain 2009 5 p. 64 10.1186/1744-8069-5-64 2-s2.0-75549089548 167 Wei M. Li L. Zhang Y. Zhang M. Su Z. Downregulated circular RNA zRANB1 mediates Wnt5a/beta-Catenin signaling to promote neuropathic pain via miR-24-3p/LPAR3 axis in CCI rat models Gene 2020 761 145038 10.1016/j.gene.2020.145038 168 Yue S. J. Liu J. Feng W. W. System pharmacology-based dissection of the synergistic mechanism of huangqi and huanglian for diabetes mellitus Frontiers in Pharmacology 2017 8 p. 694 10.3389/fphar.2017.00694 2-s2.0-85030643487 169 Chen C. M. Chen W. L. Hung C. T. Shaoyao Gancao Tang (SG-Tang), a formulated Chinese medicine, reduces aggregation and exerts neuroprotection in spinocerebellar ataxia type 17 (SCA17) cell and mouse models Aging (Albany NY) 2019 11 3 986 1007 10.18632/aging.101804 2-s2.0-85061568899 30760647 170 Jeong S. J. Lim H. S. Seo C. S. Traditional herbal formula Jakyakgamcho-tang (Paeonia lactiflora and Glycyrrhiza uralensis ) impairs inflammatory chemokine production by inhibiting activation of STAT1 and NF-κ B in HaCaT cells Phytomedicine 2015 22 2 326 332 10.1016/j.phymed.2014.12.002 2-s2.0-84923230330 25765840 171 Kang T. H. Baek H. Y. Kim Y. C. Protective effect of jakyak-gamcho-tang extract and its constituents against t-BHP-induced oxidative damage in HT22 cells The American Journal of Chinese Medicine 2005 33 2 181 189 10.1142/s0192415x05002850 2-s2.0-18744363369 15974477 172 Maeda T. Shinozuka K. Baba K. Hayashi M. Hayashi E. Effect of shakuyaku-kanzoh-toh, a prescription composed of shakuyaku (Paeoniae Radix) and kanzoh (Glycyrrhizae Radix) on Guinea pig ileum J Pharmacobiodyn 1983 6 3 153 160 10.1248/bpb1978.6.153 2-s2.0-0020561332 6875797 173 Cohen S. P. Mao J. Neuropathic pain: mechanisms and their clinical implications BMJ 2014 348 f7656 10.1136/bmj.f7656 2-s2.0-84893820251 174 Gierthmuhlen J. Baron R. Neuropathic pain Seminars in Neurology 2016 36 5 462 468 10.1055/s-0036-1584950 2-s2.0-84990822415 27704502 175 Heinzmann S. McMahon S. B. New molecules for the treatment of pain Current Opinion in Supportive and Palliative Care 2011 5 2 111 115 10.1097/spc.0b013e328345bb7e 2-s2.0-80052341057 21455071 176 Huang J. Zhang X. McNaughton P. A. Inflammatory pain: the cellular basis of heat hyperalgesia Current Neuropharmacology 2006 4 3 197 206 10.2174/157015906778019554 2-s2.0-33747235382 18615146 177 Inoue M. Rashid M. H. Fujita R. Contos J. J. Chun J. Ueda H. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling Nature Medicine 2004 10 7 712 718 10.1038/nm1060 2-s2.0-3142685946 178 Ji R. R. Strichartz G. Cell signaling and the genesis of neuropathic pain Science’s STKE 2004 252 reE14 179 Ji R. R. Xu Z. Z. Gao Y. J. Emerging targets in neuroinflammation-driven chronic pain Nature Reviews Drug Discovery 2014 13 7 533 548 10.1038/nrd4334 2-s2.0-84903814786 24948120 180 Pezet S. Marchand F. D’Mello R. Phosphatidylinositol 3-kinase is a key mediator of central sensitization in painful inflammatory conditions The Journal of Neuroscience 2008 28 16 4261 4270 10.1523/jneurosci.5392-07.2008 2-s2.0-42949128674 18417706 181 Price T. J. Basbaum A. I. Bresnahan J. Transition to chronic pain: opportunities for novel therapeutics Nature Reviews Neuroscience 2018 19 7 383 384 10.1038/s41583-018-0012-5 2-s2.0-85047019818 182 Raoof R. Willemen H. Eijkelkamp N. Divergent roles of immune cells and their mediators in pain Rheumatology (Oxford) 2018 57 3 429 440 10.1093/rheumatology/kex308 2-s2.0-85043326207 28968842 183 Sah D. W. Ossipo M. H. Porreca F. Neurotrophic factors as novel therapeutics for neuropathic pain Nature Reviews Drug discovery 2003 2 6 460 472 10.1038/nrd1107 2-s2.0-0037794324 12776221 184 Scanzello C. R. Chemokines and inflammation in osteoarthritis: insights from patients and animal models Journal of Orthopaedic Research 2017 35 4 735 739 10.1002/jor.23471 2-s2.0-85014627463 27808445 185 Sisignano M. Baron R. Scholich K. Geisslinger G. Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain Nature Reviews Neurology 2014 10 12 694 707 10.1038/nrneurol.2014.211 2-s2.0-84927176000 25366108 186 White F. A. Bhangoo S. K. Miller R. J. Chemokines: integrators of pain and inflammation Nature Reviews Drug Discovery 2005 4 10 834 844 10.1038/nrd1852 2-s2.0-27644510131 16224455 187 Calvo M. Zhu N. Tsantoulas C. Neuregulin-ErbB signaling promotes microglial proliferation and chemotaxis contributing to microgliosis and pain after peripheral nerve injury The Journal of Neuroscience 2010 30 15 5437 5450 10.1523/jneurosci.5169-09.2010 2-s2.0-77950962921 20392965 188 Chen S. P. Zhou Y. Q. Liu D. Q. PI3K/Akt pathway: a potential therapeutic target for chronic pain Current Pharmaceutical Design 2017 23 12 1860 1868 10.2174/1381612823666170210150147 2-s2.0-85020807753 28190392 189 Cui J. He W. Yi B. mTOR pathway is involved in ADP-evoked astrocyte activation and ATP release in the spinal dorsal horn in a rat neuropathic pain model Neuroscience 2014 275 395 403 10.1016/j.neuroscience.2014.06.030 2-s2.0-84904258464 24976516 190 Ding H. H. Zhang S. B. Lv Y. Y. TNF-alpha/STAT3 pathway epigenetically upregulates Nav1.6 expression in DRG and contributes to neuropathic pain induced by L5-VRT Journal of Neuroinflammation 2019 16 1 p. 29 10.1186/s12974-019-1421-8 2-s2.0-85061253731 191 Fang D. Kong L. Y. Cai J. Interleukin-6-mediated functional upregulation of TRPV1 receptors in dorsal root ganglion neurons through the activation of JAK/PI3K signaling pathway: roles in the development of bone cancer pain in a rat model Pain 2015 156 6 1124 1144 10.1097/j.pain.0000000000000158 2-s2.0-84957402169 25775359 192 Fang X. Zhou H. Huang S. Liu J. MiR-1906 attenuates neuropathic pain in rats by regulating the TLR4/mTOR/akt signaling pathway Translational Neuroscience 2019 10 175 179 10.1515/tnsci-2019-0031 2-s2.0-85070640540 31410300 193 Feng X. L. Deng H. B. Wang Z. G. Wu Y. Ke J. J. Feng X. B. Suberoylanilide hydroxamic acid triggers autophagy by influencing the mTOR pathway in the spinal dorsal horn in a rat neuropathic pain model Neurochemical Research 2019 44 2 450 464 10.1007/s11064-018-2698-1 2-s2.0-85058706965 30560396 194 Gu W. Sun Y. Gu W. The analgesic effects of pioglitazone in the bone cancer pain rats via regulating the PPARγ /PTEN/mTOR signaling pathway in the spinal dorsal horn Biomedicine & Pharmacotherapy 2020 131 110692 10.1016/j.biopha.2020.110692 195 Gui Y. Li A. Chen F. Involvement of AMPK/SIRT1 pathway in anti-allodynic effect of troxerutin in CCI-induced neuropathic pain European Journal of Pharmacology 2015 769 234 241 10.1016/j.ejphar.2015.11.023 2-s2.0-84949008348 26601804 196 Hao S. Mata M. Glorioso J. C. Fink D. J. Gene transfer to interfere with TNFalpha signaling in neuropathic pain Gene Therapy 2007 14 13 1010 1016 10.1038/sj.gt.3302950 2-s2.0-34250766660 17443214 197 Huang J. Chen D. Yan F. JTC-801 alleviates mechanical allodynia in paclitaxel-induced neuropathic pain through the PI3K/Akt pathway European Journal of Pharmacology 2020 883 173306 10.1016/j.ejphar.2020.173306 198 Jiang S. P. Zhang Z. D. Kang L. M. Wang Q. H. Zhang L. Chen H. P. Celecoxib reverts oxaliplatin-induced neuropathic pain through inhibiting PI3K/Akt2 pathway in the mouse dorsal root ganglion Experimental Neurology 2016 275 1 11 16 10.1016/j.expneurol.2015.11.001 2-s2.0-84946882392 26546510 199 Kun L. Lu L. Yongda L. Xingyue L. Guang H. Hyperbaric oxygen promotes mitophagy by activating CaMKKβ /AMPK signal pathway in rats of neuropathic pain Molecular Pain 2019 15 1744806919871381 10.1177/1744806919871381 2-s2.0-85071709844 200 Lee G. W. Son J. Y. Lee A. R. Ju J. S. Bae Y. C. Ahn D. K. Central VEGF-A pathway plays a key role in the development of trigeminal neuropathic pain in rats Molecular Pain 2019 15 1744806919872602 10.1177/1744806919872602 2-s2.0-85071919867 201 Liu Y. D. Wang Z. B. Han G. Jin L. Zhao P. Hyperbaric oxygen relieves neuropathic pain through AKT/TSC2/mTOR pathway activity to induce autophagy Journal of Pain Research 2019 12 443 451 10.2147/jpr.s189353 2-s2.0-85062341426 30774414 202 Liu Y. D. Wang Z. B. Han G. Zhao P. Hyperbaric oxygen treatment attenuates neuropathic pain by elevating autophagy flux via inhibiting mTOR pathway American Journal of Translational Research 2017 9 5 2629 2638 28560010 203 Lu Y. Jiang B. C. Cao D. L. TRAF6 upregulation in spinal astrocytes maintains neuropathic pain by integrating TNF-alpha and IL-1β signaling Pain 2014 155 12 2618 2629 10.1016/j.pain.2014.09.027 2-s2.0-84922697989 25267210 204 Maixner D. W. Yan X. Gao M. Yadav R. Weng H. R. Adenosine monophosphate-activated protein kinase regulates interleukin-1β expression and glial glutamate transporter function in rodents with neuropathic pain Anesthesiology 2015 122 6 1401 1413 10.1097/aln.0000000000000619 2-s2.0-84930969726 25710409 205 Mejia G. L. Asiedu M. N. Hitoshi Y. Dussor G. Price T. J. The potent, indirect adenosine monophosphate- activated protein kinase activator R419 attenuates mitogen-activated protein kinase signaling, inhibits nociceptor excitability, and reduces pain hypersensitivity in mice Pain Reports 2016 1 1 e562 10.1097/pr9.0000000000000562 206 Obara I. Tochiki K. K. Geranton S. M. Systemic inhibition of the mammalian target of rapamycin (mTOR) pathway reduces neuropathic pain in mice Pain 2011 152 11 2582 2595 10.1016/j.pain.2011.07.025 2-s2.0-80054991423 21917376 207 Price T. J. Das V. Dussor G. Adenosine monophosphate-activated protein kinase (AMPK) activators for the prevention, treatment and potential reversal of pathological pain Current Drug Targets 2016 17 8 908 920 10.2174/1389450116666151102095046 26521775 208 Sabsovich I. Guo T. Z. Wei T. TNF signaling contributes to the development of nociceptive sensitization in a tibia fracture model of complex regional pain syndrome type I Pain 2008 137 3 507 519 10.1016/j.pain.2007.10.013 2-s2.0-47249113399 18035493 209 Shi J. Jiang K. Li Z. MiR-145 ameliorates neuropathic pain via inhibiting inflammatory responses and mTOR signaling pathway by targeting Akt3 in a rat model Neuroscience Research 2018 134 10 17 10.1016/j.neures.2017.11.006 2-s2.0-85034859331 29162479 210 Sobeh M. Mahmoud M. F. Rezq S. Haematoxylon campechianum extract ameliorates neuropathic pain via inhibition of NF-κ B/TNF-α /NOX/iNOS signalling pathway in a rat model of chronic constriction injury Biomolecules 2020 10 3 p. 386 10.3390/biom10030386 211 Sobeh M. Mahmoud M. F. Rezq S. Salix tetrasperma roxb. Extract alleviates neuropathic pain in rats via modulation of the NF-κ B/TNF-α /NOX/iNOS pathway Antioxidants (Basel) 2019 8 10 p. 482 10.3390/antiox8100482 2-s2.0-85073760964 212 Song H. Han Y. Pan C. Activation of adenosine monophosphate-activated protein kinase suppresses neuroinflammation and ameliorates bone cancer pain: involvement of inhibition on mitogen-activated protein kinase Anesthesiology 2015 123 5 1170 1185 10.1097/aln.0000000000000856 2-s2.0-84944345085 26378398 213 Tao F. Li Q. Liu S. Role of neuregulin-1/ErbB signaling in stem cell therapy for spinal cord injury-induced chronic neuropathic pain Stem Cells 2013 31 1 83 91 10.1002/stem.1258 2-s2.0-84871541707 23097328 214 Wang R. Qiu Z. Wang G. Quercetin attenuates diabetic neuropathic pain by inhibiting mTOR/p70S6K pathway-mediated changes of synaptic morphology and synaptic protein levels in spinal dorsal horn of db/db mice European Journal of Pharmacology 2020 882 173266 10.1016/j.ejphar.2020.173266 215 Xie X. Ma L. Xi K. Zhang W. Fan D. MicroRNA-183 suppresses neuropathic pain and expression of AMPA receptors by targeting mTOR/VEGF signaling pathway Cell Physiol Biochem 2017 41 1 181 192 10.1159/000455987 2-s2.0-85021854002 28214854 216 Xing X. Wu K. Dong Y. Hyperactive Akt-mTOR pathway as a therapeutic target for pain hypersensitivity in Cntnap2-deficient mice Neuropharmacology 2020 165 107816 10.1016/j.neuropharm.2019.107816 217 Yang G. Tan Q. Li Z. The AMPK pathway triggers autophagy during CSF1-induced microglial activation and may be implicated in inducing neuropathic pain Journal of Neuroimmunology 2020 345 577261 10.1016/j.jneuroim.2020.577261 218 Yang Q. Q. Li H. N. Zhang S. T. Red nucleus IL-6 mediates the maintenance of neuropathic pain by inducing the productions of TNF-α and IL-1β through the JAK2/STAT3 and ERK signaling pathways Neuropathology 2020 40 4 10.1111/neup.12653 219 Yuan L. Liu C. Wan Y. Yan H. Li T. Effect of HDAC2/Inpp5f on neuropathic pain and cognitive function through regulating PI3K/Akt/GSK-3β signal pathway in rats with neuropathic pain Experimental and Therapeutic Medicine 2019 18 1 678 684 10.3892/etm.2019.7622 31281447 220 Zhang J. Wang L. Wang H. Su Z. Pang X. Neuroinflammation and central PI3K/Akt/mTOR signal pathway contribute to bone cancer pain Molecular Pain 2019 15 1744806919830240 10.1177/1744806919830240 2-s2.0-85062185941 221 Zhang Q. Yu J. Wang J. The red nucleus TNF-alpha participates in the initiation and maintenance of neuropathic pain through different signaling pathways Neurochemical Research 2015 40 7 1360 1371 10.1007/s11064-015-1599-9 2-s2.0-84938209384 25952358 222 Zhang W. Bai Y. Qiao Y. 8-O-acetyl shanzhiside methylester from lamiophlomis rotata reduces neuropathic pain by inhibiting the ERK/TNF-alpha pathway in spinal astrocytes Frontiers in Cellular Neuroscience 2018 12 p. 54 10.3389/fncel.2018.00054 2-s2.0-85046682307 223 Zhang Y. Yuan L. Chen Y. Lin C. Ye G. Oxyntomodulin attenuates TNFα induced neuropathic pain by inhibiting the activation of the NFκ B pathway Molecular Medicine Reports 2019 20 6 5223 5228 10.3892/mmr.2019.10770 31661136 224 Zhang Z. Deng M. Huang J. Microglial annexin A3 downregulation alleviates bone cancer-induced pain via inhibiting the Hif-1alpha/VEGF signaling pathway Pain 2020 161 12 2750 2762 10.1097/j.pain.0000000000001962 32569086 225 Zhao D. Han D. F. Wang S. S. Lv B. Wang X. Ma C. Roles of tumor necrosis factor-alpha and interleukin-6 in regulating bone cancer pain via TRPA1 signal pathway and beneficial effects of inhibition of neuro-inflammation and TRPA1 Molecular Pain 2019 15 1744806919857981 10.1177/1744806919857981 2-s2.0-85067896428 226 Ji A. Zhu M. Effects of curcumin on biological behavior and NF-κ B/TNF-α pathway in mice with metastatic bone pain of breast cancer induced by walker 256 cells J Cancer Ther 2020 11 6 p. 339 10.4236/jct.2020.116028 227 Dehghani S. Alipoor E. Salimzadeh A. The effect of a garlic supplement on the pro-inflammatory adipocytokines, resistin and tumor necrosis factor-alpha, and on pain severity, in overweight or obese women with knee osteoarthritis Phytomedicine 2018 48 70 75 10.1016/j.phymed.2018.04.060 2-s2.0-85050890068 30195882 228 Tian Y. Wang S. Ma Y. Lim G. Kim H. Mao J. Leptin enhances NMDA-induced spinal excitation in rats: a functional link between adipocytokine and neuropathic pain Pain 2011 152 6 1263 1271 10.1016/j.pain.2011.01.054 2-s2.0-79956065269 21376468 229 Ji R. Zhuang Z. Xu H. Clapham D. J. T. J. o.P. Phosphatidylinositol 3-kinase (PI3K) cascade is a novel signaling pathway to mediate inflammatory pain Journal of Pain 2005 6 3 S11 10.1016/j.jpain.2005.01.040 230 Ji Y. Tang B. Traub R. J. Spinal estrogen receptor alpha mediates estradiol-induced pronociception in a visceral pain model in the rat Pain 2011 152 5 1182 1191 10.1016/j.pain.2011.01.046 2-s2.0-79954584498 21392887 231 Khariv V. Acioglu C. Ni L. A link between plasma membrane calcium ATPase 2 (PMCA2), estrogen and estrogen receptor alpha signaling in mechanical pain Scientific Reports 2018 8 1 17260 10.1038/s41598-018-35263-0 2-s2.0-85057106382 232 Piu F. Cheevers C. Hyldtoft L. Broad modulation of neuropathic pain states by a selective estrogen receptor beta agonist European Journal of Pharmacology 2008 590 1–3 423 429 10.1016/j.ejphar.2008.05.015 2-s2.0-48049099210 18559275 233 Tang B. Ji Y. Traub R. J. Estrogen alters spinal NMDA receptor activity via a PKA signaling pathway in a visceral pain model in the rat Pain 2008 137 3 540 549 10.1016/j.pain.2007.10.017 2-s2.0-47249153612 18068901 234 Yan X. J. Feng C. C. Liu Q. Vagal afferents mediate antinociception of estrogen in a rat model of visceral pain: the involvement of intestinal mucosal mast cells and 5-hydroxytryptamine 3 signaling The Journal of Pain 2014 15 2 204 217 10.1016/j.jpain.2013.10.012 2-s2.0-84895071033 24231720 235 Zielinska M. Fichna J. Bashashati M. G protein-coupled estrogen receptor and estrogen receptor ligands regulate colonic motility and visceral pain Neurogastroenterology & Motility 2017 29 7 e13025 10.1111/nmo.13025 2-s2.0-85012295521 236 Busch-Dienstfertig M. Gonzalez-Rodriguez S. IL-4, JAK-STAT signaling, and pain JAKSTAT 2013 2 4 e27638 10.4161/jkst.27638 237 Cao S. Li Y. Wang L. Synergistic analgesic effect of propofol-alfentanil combination through detecting the inhibition of cAMP signal pathway Journal of Pharmacy and Pharmacology 2016 68 9 1170 1176 10.1111/jphp.12578 2-s2.0-84981287730 27334358 238 Chen S. P. Sun J. Zhou Y. Q. Sinomenine attenuates cancer-induced bone pain via suppressing microglial JAK2/STAT3 and neuronal CAMKII/CREB cascades in rat models Molecular Pain 2018 14 1744806918793232 10.1177/1744806918793232 2-s2.0-85055096911 239 Hang L. H. Yang J. P. Shao D. H. Chen Z. Wang H. Involvement of spinal PKA/CREB signaling pathway in the development of bone cancer pain Pharmacological Reports 2013 65 3 710 716 10.1016/s1734-1140(13)71049-1 2-s2.0-84884472665 23950594 240 Hsiao H. T. Lin Y. C. Wang J. C. Tsai Y. C. Liu Y. C. Hypoxia inducible factor-1α inhibition produced anti-allodynia effect and suppressed inflammatory cytokine production in early stage of mouse complex regional pain syndrome model Clinical and Experimental Pharmacology and Physiology 2016 43 3 355 359 10.1111/1440-1681.12536 2-s2.0-84959353712 26711019 241 Hsiao H. T. Liu Y. Y. Wang J. C. Lin Y. C. Liu Y. C. The analgesic effect of propofol associated with the inhibition of hypoxia inducible factor and inflammasome in complex regional pain syndrome Journal of Biomedical Science 2019 26 1 p. 74 10.1186/s12929-019-0576-z 2-s2.0-85073633911 242 Hsieh Y. L. Chou L. W. Chang P. L. Yang C. C. Kao M. J. Hong C. Z. Low-level laser therapy alleviates neuropathic pain and promotes function recovery in rats with chronic constriction injury: possible involvements in hypoxia-inducible factor 1alpha (HIF-1α ) The Journal of Comparative Neurology 2012 520 13 2903 2916 10.1002/cne.23072 2-s2.0-84863598560 22351621 243 Kallenborn-Gerhardt W. Metzner K. Lu R. Neuropathic and cAMP-induced pain behavior is ameliorated in mice lacking CNGB1 Neuropharmacology 2020 171 108087 10.1016/j.neuropharm.2020.108087 244 Kober K. M. Lee M. C. Olshen A. Differential methylation and expression of genes in the hypoxia-inducible factor 1 signaling pathway are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors and with preclinical models of chemotherapy-induced neuropathic pain Molecular Pain 2020 16 1744806920936502 10.1177/1744806920936502 245 Liou J. T. Liu F. C. Hsin S. T. Yang C. Y. Lui P. W. Inhibition of the cyclic adenosine monophosphate pathway attenuates neuropathic pain and reduces phosphorylation of cyclic adenosine monophosphate response element-binding in the spinal cord after partial sciatic nerve ligation in rats Anesthesia & Analgesia 2007 105 6 1830 1837 10.1213/01.ane.0000287652.42309.5c 2-s2.0-36549038179 18042889 246 Ludman T. Melemedjian O. K. Bortezomib and metformin opposingly regulate the expression of hypoxia-inducible factor alpha and the consequent development of chemotherapy-induced painful peripheral neuropathy Molecular Pain 2019 15 1744806919850043 10.1177/1744806919850043 2-s2.0-85065676479 247 Rojas D. R. Tegeder I. Kuner R. Agarwal N. Hypoxia-inducible factor 1alpha protects peripheral sensory neurons from diabetic peripheral neuropathy by suppressing accumulation of reactive oxygen species Journal of Molecular Medicine 2018 96 12 1395 1405 10.1007/s00109-018-1707-9 2-s2.0-85055694488 30361814 248 Salaffi F. Giacobazzi G. Di Carlo M. Chronic pain in inflammatory arthritis: mechanisms, metrology, and emerging targets-A focus on the JAK-STAT pathway Pain Research and Management 2018 2018 14 8564215 10.1155/2018/8564215 2-s2.0-85042586716 249 Salehi F. Hosseini-Zare M. S. Aghajani H. Seyedi S. Y. Hosseini-Zare M. S. Sharifzadeh M. Effect of bucladesine, pentoxifylline, and H-89 as cyclic adenosine monophosphate analog, phosphodiesterase, and protein kinase A inhibitor on acute pain Fundamental & Clinical Pharmacology 2017 31 4 411 419 10.1111/fcp.12282 2-s2.0-85018343655 28267871 250 Shao X. M. Sun J. Jiang Y. L. Inhibition of the cAMP/PKA/CREB pathway contributes to the analgesic effects of electroacupuncture in the anterior cingulate cortex in a rat pain memory model Neural Plasticity 2016 2016 16 5320641 10.1155/2016/5320641 2-s2.0-85008958155 251 Tang J. Li Z. H. Ge S. N. The inhibition of spinal astrocytic JAK2-STAT3 pathway activation correlates with the analgesic effects of triptolide in the rat neuropathic pain model Evidence-Based Complementary and Alternative Medicine 2012 2012 13 185167 10.1155/2012/185167 2-s2.0-84872794619 252 Wang H. Huo X. Chen H. Hydrogen-rich saline activated autophagy via HIF-1alpha pathways in neuropathic pain model BioMed Research International 2018 2018 4670834 10.1155/2018/4670834 2-s2.0-85047875423 253 Xiong Z. Ding J. Zhou J. Yao S. Zheng J. Guo X. Correlation between the HIF-1α /Notch signaling pathway and Modic changes in nucleus pulposus cells isolated from patients with low back pain BMC Musculoskeletal Disorders 2020 21 1 p. 500 10.1186/s12891-020-03505-w 254 Xun S. Zheng R. Dexmedetomidine alleviates neuropathic pain by regulating JAK/STAT pathway in rats Journal of Cellular Biochemistry 2020 121 3 2277 2283 10.1002/jcb.29450 31674072 255 Zhang G. Feng G. Y. Guo Y. R. Liang D. Q. Yuan Y. Wang H. L. Correlation between liver cancer pain and the HIF-1 and VEGF expression levels Oncology Letters 2017 13 1 77 80 10.3892/ol.2016.5405 2-s2.0-85003837152 28123525 256 Zhu G. Q. Liu S. He D. D. Liu Y. P. Song X. J. Activation of the cAMP-PKA signaling pathway in rat dorsal root ganglion and spinal cord contributes toward induction and maintenance of bone cancer pain Behavioural Pharmacology 2014 25 4 267 276 10.1097/fbp.0000000000000048 2-s2.0-84904204772 24978483 257 Skyba D. A. Radhakrishnan R. Bement M. K. H. Sluka K. A. The cAMP pathway and pain: potential targets for drug development Drug Discovery Today: Disease Models 2004 1 2 115 119 10.1016/j.ddmod.2004.07.003 2-s2.0-23744502252 258 Androutsopoulos V. P. Ruparelia K. Arroo R. R. Tsatsakis A. M. Spandidos D. A. CYP1-mediated antiproliferative activity of dietary flavonoids in MDA-MB-468 breast cancer cells Toxicology 2009 264 3 162 170 10.1016/j.tox.2009.07.023 2-s2.0-70349213212 19666078 259 Chao M. V. Rajagopal R. Lee F. S. Neurotrophin signalling in health and disease Clinical Science (London) 2006 110 2 167 173 10.1042/cs20050163 2-s2.0-32644451922 260 Hu X. M. Zhang H. Xu H. Chemokine receptor CXCR4 regulates CaMKII/CREB pathway in spinal neurons that underlies cancer-induced bone pain Scientific Reports 2017 7 1 4005 10.1038/s41598-017-04198-3 2-s2.0-85021226084 261 Khan N. Smith M. T. Neurotrophins and neuropathic pain: role in pathobiology Molecules 2015 20 6 10657 10688 10.3390/molecules200610657 2-s2.0-84938352476 26065639 262 Mannion R. J. Costigan M. Decosterd I. Neurotrophins: peripherally and centrally acting modulators of tactile stimulus-induced inflammatory pain hypersensitivity Proceedings of the National Academy of Sciences of the United States of America 1999 96 16 9385 9390 10.1073/pnas.96.16.9385 2-s2.0-13044251808 10430952 263 Pezet S. McMahon S. B. Neurotrophins: mediators and modulators of pain Annual Review of Neuroscience 2006 29 507 538 10.1146/annurev.neuro.29.051605.112929 2-s2.0-33748375335 264 Xu H. Peng C. Chen X. T. Chemokine receptor CXCR4 activates the RhoA/ROCK2 pathway in spinal neurons that induces bone cancer pain Molecular Pain 2020 16 1744806920919568 10.1177/1744806920919568 265 Zhang Q. Cao D. L. Zhang Z. J. Jiang B. C. Gao Y. J. Chemokine CXCL13 mediates orofacial neuropathic pain via CXCR5/ERK pathway in the trigeminal ganglion of mice Journal of Neuroinflammation 2016 13 1 p. 183 10.1186/s12974-016-0652-1 2-s2.0-84979020337 266 Brussee V. Cunningham F. A. Zochodne D. W. Direct insulin signaling of neurons reverses diabetic neuropathy Diabetes 2004 53 7 1824 1830 10.2337/diabetes.53.7.1824 2-s2.0-3042785971 15220207 267 Dobretsov M. Ghaleb A. H. Romanovsky D. Pablo C. S. Stimers J. R. Impaired insulin signaling as a potential trigger of pain in diabetes and prediabetes International Anesthesiology Clinics 2007 45 2 95 105 10.1097/aia.0b013e31803419c3 2-s2.0-34247266688 17426511 268 Sharma S. Chopra K. Kulkarni S. K. Effect of insulin and its combination with resveratrol or curcumin in attenuation of diabetic neuropathic pain: participation of nitric oxide and TNF-alpha Phytotherapy Research 2007 21 3 278 283 10.1002/ptr.2070 2-s2.0-33947579407 17199240 269 Sugimoto K. Rashid I. B. Shoji M. Suda T. Yasujima M. Early changes in insulin receptor signaling and pain sensation in streptozotocin-induced diabetic neuropathy in rats The Journal of Pain 2008 9 3 237 245 10.1016/j.jpain.2007.10.016 2-s2.0-39449091024 18331706 270 Banimostafavi E. S. Fakhar M. Abediankenari S. Determining serum levels of IL-10 and IL-17 in patients with low back pain caused by lumbar disc degeneration Infectious Disorders Drug Targets 2020 10.2174/1871526520666200820093924 271 Day Y. J. Liou J. T. Lee C. M. Lack of interleukin-17 leads to a modulated micro-environment and amelioration of mechanical hypersensitivity after peripheral nerve injury in mice Pain 2014 155 7 1293 1302 10.1016/j.pain.2014.04.004 2-s2.0-84902329683 24721689 272 Hu X. Huang F. Wang Z. J. CaMKIIalpha mediates the effect of IL-17 to promote ongoing spontaneous and evoked pain in multiple sclerosis The Journal of Neuroscience 2018 38 1 232 244 10.1523/jneurosci.2666-17.2017 2-s2.0-85040074504 29146590 273 Kim C. F. Moalem-Taylor G. Interleukin-17 contributes to neuroinflammation and neuropathic pain following peripheral nerve injury in mice The Journal of Pain 2011 12 3 370 383 10.1016/j.jpain.2010.08.003 2-s2.0-79952440651 20889388 274 Liu X. Fan S. Zheng M. Chen J. Zhang J. Li H. The mediation of interleukin-17 and chemokine ligand 2 in pelvic pain of experimental autoimmune prostatitis Experimental and Therapeutic Medicine 2017 14 1 51 58 10.3892/etm.2017.4448 2-s2.0-85020539744 28672892 275 Luo H. Liu H. Z. Zhang W. W. Interleukin-17 regulates neuron-glial communications, synaptic transmission, and neuropathic pain after chemotherapy Cell Reports 2019 29 8 2384.e5 2397.e5 10.1016/j.celrep.2019.10.085 31747607 276 Meng X. Zhang Y. Lao L. Spinal interleukin-17 promotes thermal hyperalgesia and NMDA NR1 phosphorylation in an inflammatory pain rat model Pain 2013 154 2 294 305 10.1016/j.pain.2012.10.022 2-s2.0-84872685685 23246025 277 Noma N. Khan J. Chen I. F. Interleukin-17 levels in rat models of nerve damage and neuropathic pain Neuroscience Letters 2011 493 3 86 91 10.1016/j.neulet.2011.01.079 2-s2.0-79952898726 21316418 278 Richter F. Natura G. Ebbinghaus M. Interleukin-17 sensitizes joint nociceptors to mechanical stimuli and contributes to arthritic pain through neuronal interleukin-17 receptors in rodents Arthritis & Rheumatology 2012 64 12 4125 4134 10.1002/art.37695 2-s2.0-84870323722 279 Sun C. Zhang J. Chen L. IL-17 contributed to the neuropathic pain following peripheral nerve injury by promoting astrocyte proliferation and secretion of proinflammatory cytokines Molecular Medicine Reports 2017 15 1 89 96 10.3892/mmr.2016.6018 2-s2.0-85006341311 27959414 280 Yao C. Y. Weng Z. L. Zhang J. C. Feng T. Lin Y. Yao S. Interleukin-17A acts to maintain neuropathic pain through activation of CaMKII/CREB signaling in spinal neurons Molecular Neurobiology 2016 53 6 3914 3926 10.1007/s12035-015-9322-z 2-s2.0-84937012957 26166359 281 Zhang W. Nie L. Guo Y. J. Th17 cell frequency and IL-17 concentration correlate with pre- and postoperative pain sensation in patients with intervertebral disk degeneration Orthopedics 2014 37 7 e685 e691 10.3928/01477447-20140626-62 2-s2.0-84905659791 282 Zou D. Zhang K. Yang Y. Th17 and IL-17 exhibit higher levels in osteonecrosis of the femoral head and have a positive correlation with severity of pain Endokrynologia Polska 2018 69 3 283 290 10.5603/ep.a2018.0031 2-s2.0-85055774396 29952419 283 Bieglmayer C. Hofer G. Kainz C. Reinthaller A. Kopp B. Janisch H. Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives Gynecological Endocrinology 1995 9 4 307 312 10.3109/09513599509160464 2-s2.0-0029587265 8629459 284 Sinning C. Watzer B. De Petrocellis L. Di Marzo V. Imming P. Dopamides, vanillylamides, ethanolamides, and arachidonic acid amides of anti-inflammatory and analgesic drug substances as TRPV1 ligands ChemMedChem 2008 3 12 1956 1964 10.1002/cmdc.200800271 2-s2.0-57549112238 19003845 285 Smith H. S. Arachidonic acid pathways in nociception The Journal of Supportive Oncology 2006 4 6 277 287 16805330 286 Sung B. Wang S. Zhou B. Altered spinal arachidonic acid turnover after peripheral nerve injury regulates regional glutamate concentration and neuropathic pain behaviors in rats Pain 2007 131 1-2 121 131 10.1016/j.pain.2006.12.020 2-s2.0-34547587094 17267128 287 Yang W. Yaggie R. E. Schaeffer A. J. Klumpp D. J. AOAH remodels arachidonic acid-containing phospholipid pools in a model of interstitial cystitis pain: a MAPP network study PLoS One 2020 15 9 e0235384 10.1371/journal.pone.0235384 288 Wang X. Wu T. Lee Y. Dionne R. J. C. P. Therapeutics Gene expression in the arachidonic acid pathway due to tissue injury and inflammation, an NSAID, and COXIB in a clinical model of pain Clinical Pharmacology & Therapeutics 2005 77 2 p. P8 10.1016/j.clpt.2004.11.034 289 Haleem D. J. Nawaz S. Salman T. Dopamine and serotonin metabolism associated with morphine reward and its inhibition with buspirone: a study in the rat striatum Pharmacology Biochemistry and Behavior 2018 170 71 78 10.1016/j.pbb.2018.05.010 2-s2.0-85047431137 290 Li N. Li C. Han R. LPM580098, a novel triple reuptake inhibitor of serotonin, noradrenaline, and dopamine, attenuates neuropathic pain Frontiers in Pharmacology 2019 10 p. 53 10.3389/fphar.2019.00053 2-s2.0-85065921184 291 Martikainen I. K. Hagelberg N. Jaaskelainen S. K. Hietala J. Pertovaara A. Dopaminergic and serotonergic mechanisms in the modulation of pain: in vivo studies in human brain European Journal of Pharmacology 2018 834 337 345 10.1016/j.ejphar.2018.07.038 2-s2.0-85050873170 30036531 292 Sagheddu C. Aroni S. De Felice M. Enhanced serotonin and mesolimbic dopamine transmissions in a rat model of neuropathic pain Neuropharmacology 2015 97 383 393 10.1016/j.neuropharm.2015.06.003 2-s2.0-84934756066 26113399 293 Li L. Qiu H. Liu M. Cai Y. A network pharmacology-based study of the molecular mechanisms of shaoyao-gancao decoction in treating Parkinson’s disease Interdisciplinary Sciences 2020 12 2 131 144 10.1007/s12539-020-00359-7 294 Zhu N. Hou J. Ma G. Liu J. Network pharmacology identifies the mechanisms of action of shaoyao gancao decoction in the treatment of osteoarthritis Medical Science Monitor 2019 25 6051 6073 10.12659/msm.915821 2-s2.0-85071280542 31409761 295 Addepalli V. Suryavanshi S. V. Catechin attenuates diabetic autonomic neuropathy in streptozotocin induced diabetic rats Biomedicine & Pharmacotherapy 2018 108 1517 1523 10.1016/j.biopha.2018.09.179 2-s2.0-85054434006 30372853 296 Deciga-Campos M. Mata R. Rivero-Cruz I. Antinociceptive pharmacological profile of dysphania graveolens in mouse Biomedicine & Pharmacotherapy 2017 89 933 938 10.1016/j.biopha.2017.02.096 2-s2.0-85014708817 28292021 297 Islam S. Shajib M. S. Rashid R. B. Antinociceptive activities of Artocarpus lacucha Buch-ham (Moraceae) and its isolated phenolic compound, catechin, in mice BMC Complementary and Alternative Medicine 2019 19 1 p. 214 10.1186/s12906-019-2565-x 2-s2.0-85070975499 31412852 298 Zhang Y. Sun D. Meng Q. Guo W. Chen Q. Zhang Y. Calcium channels contribute to albiflorin-mediated antinociceptive effects in mouse model Neuroscience Letters 2016 628 105 109 10.1016/j.neulet.2016.03.054 2-s2.0-84975500492 27038516 299 Lima Cavendish R. de Souza Santos J. Belo Neto R. Antinociceptive and anti-inflammatory effects of Brazilian red propolis extract and formononetin in rodents Journal of Ethnopharmacology 2015 173 127 133 10.1016/j.jep.2015.07.022 2-s2.0-84938316964 26192808 300 Parlar A. Arslan S. O. Cam S. A. Glabridin alleviates inflammation and nociception in rodents by activating BKCa channels and reducing NO levels Biological and Pharmaceutical Bulletin 2020 43 5 884 897 10.1248/bpb.b20-00038 32147624 301 Wang H. L. Li Y. X. Niu Y. T. Observing anti-inflammatory and anti-nociceptive activities of glycyrrhizin through regulating COX-2 and pro-inflammatory cytokines expressions in mice Inflammation 2015 38 6 2269 2278 10.1007/s10753-015-0212-3 2-s2.0-84946491101 26178479 302 Wang X. S. Guan S. Y. Liu A. Anxiolytic effects of formononetin in an inflammatory pain mouse model Mol Brain 2019 12 1 p. 36 10.1186/s13041-019-0453-4 2-s2.0-85064111261 303 Farbood Y. Sarkaki A. Hashemi S. Mansouri M. T. Dianat M. The effects of gallic acid on pain and memory following transient global ischemia/reperfusion in Wistar rats Avicenna Journal of Phytomedicine 2013 3 4 329 340 25050290 304 Hajimoradi M. Fazilati M. Gharib-Naseri M. K. Sarkaki A. Gallic acid and exercise training improve motor function, nerve conduction velocity but not pain sense reflex after experimental sciatic nerve crush in male rats Avicenna Journal of Phytomedicine 2015 5 4 288 297 26445710 305 Feldman P. Due M. R. Ripsch M. S. Khanna R. White F. A. The persistent release of HMGB1 contributes to tactile hyperalgesia in a rodent model of neuropathic pain Journal of Neuroinflammation 2012 9 180 10.1186/1742-2094-9-180 2-s2.0-84868359842 306 Hu C. Y. Zhao Y. T. Analgesic effects of naringenin in rats with spinal nerve ligation-induced neuropathic pain Biomedical Reports 2014 2 4 569 573 10.3892/br.2014.267 24944810 307 Manchope M. F. Calixto-Campos C. Coelho-Silva L. Naringenin inhibits superoxide anion-induced inflammatory pain: role of oxidative stress, cytokines, nrf-2 and the NO-cGMP-PKG-KATP channel signaling pathway PLoS One 2016 11 4 e0153015 10.1371/journal.pone.0153015 2-s2.0-84963636088 308 Manchope M. F. Casagrande R. Verri W. A. Jr. Naringenin: an analgesic and anti-inflammatory citrus flavanone Oncotarget 2017 8 3 3766 3767 10.18632/oncotarget.14084 2-s2.0-85012022789 28030851 309 Pinho-Ribeiro F. A. Zarpelon A. C. Fattori V. Naringenin reduces inflammatory pain in mice Neuropharmacology 2016 105 508 519 10.1016/j.neuropharm.2016.02.019 2-s2.0-84961662283 26907804 310 Pinho-Ribeiro F. A. Zarpelon A. C. Mizokami S. S. The citrus flavonone naringenin reduces lipopolysaccharide-induced inflammatory pain and leukocyte recruitment by inhibiting NF-κ B activation The Journal of Nutritional Biochemistry 2016 33 8 14 10.1016/j.jnutbio.2016.03.013 2-s2.0-84971320433 27260463 311 Singh P. Bansal S. Kuhad A. Kumar A. Chopra K. Naringenin ameliorates diabetic neuropathic pain by modulation of oxidative-nitrosative stress, cytokines and MMP-9 levels Food & Function 2020 11 5 4548 4560 10.1039/c9fo00881k 32400767 312 Xue N. Wu X. Wu L. Li L. Wang F. Antinociceptive and anti-inflammatory effect of naringenin in different nociceptive and inflammatory mice models Life Sciences 2019 217 148 154 10.1016/j.lfs.2018.11.013 2-s2.0-85057619105 30414428 313 Ruiz-Miyazawa K. W. Borghi S. M. Pinho-Ribeiro F. A. The citrus flavanone naringenin reduces gout-induced joint pain and inflammation in mice by inhibiting the activation of NFκ B and macrophage release of IL-1β Journal of Functional Foods 2018 48 106 116 10.1016/j.jff.2018.06.025 2-s2.0-85049857251 314 Dallazen J. L. da Silva C. F. Hamm L. Further antinociceptive properties of naringenin on acute and chronic pain in mice Natural Product Communications 2017 12 9 1934578X1701200915 10.1177/1934578x1701200915 315 Sato Y. He J. X. Nagai H. Tani T. Akao T. Isoliquiritigenin, one of the antispasmodic principles of Glycyrrhiza ularensis roots, acts in the lower part of intestine Biological and Pharmaceutical Bulletin 2007 30 1 145 149 10.1248/bpb.30.145 2-s2.0-33846055491 17202675 316 Shi Y. Wu D. Sun Z. Analgesic and uterine relaxant effects of isoliquiritigenin, a flavone from Glycyrrhiza glabra Phytotherapy Research 2012 26 9 1410 1417 10.1002/ptr.3715 2-s2.0-84866069562 22389128 317 Jamali-Raeufy N. Baluchnejadmojarad T. Roghani M. Keimasi S. Goudarzi M. Isorhamnetin exerts neuroprotective effects in STZ-induced diabetic rats via attenuation of oxidative stress, inflammation and apoptosis Journal of Chemical Neuroanatomy 2019 102 101709 10.1016/j.jchemneu.2019.101709 318 Kim S. H. Park J. G. Sung G. H. Kaempferol, a dietary flavonoid, ameliorates acute inflammatory and nociceptive symptoms in gastritis, pancreatitis, and abdominal pain Molecular Nutrition & Food Research 2015 59 7 1400 1405 10.1002/mnfr.201400820 2-s2.0-84934440168 25917334 319 Kishore L. Kaur N. Singh R. Effect of kaempferol isolated from seeds of Eruca sativa on changes of pain sensitivity in streptozotocin-induced diabetic neuropathy Inflammopharmacology 2018 26 4 993 1003 10.1007/s10787-017-0416-2 2-s2.0-85034579819 29159712 320 Parveen Z. Deng Y. Saeed M. K. Dai R. Ahamad W. Yu Y. H. Antiinflammatory and analgesic activities of Thesium chinense Turcz extracts and its major flavonoids, kaempferol and kaempferol-3-O-glucoside Yakugaku Zasshi 2007 127 8 1275 1279 10.1248/yakushi.127.1275 2-s2.0-34547624548 17666881 321 Ahangarpour A. Oroojan A. A. Khorsandi L. Shabani R. Mojaddami S. Preventive effects of betulinic acid on streptozotocinnicotinamide induced diabetic nephropathy in male mouse Journal of Nephropathology 2016 5 4 128 133 10.15171/jnp.2016.24 2-s2.0-84983372105 27921024 322 Bellampalli S. S. Ji Y. Moutal A. Betulinic acid, derived from the desert lavender Hyptis emoryi , attenuates paclitaxel-, HIV-, and nerve injury-associated peripheral sensory neuropathy via block of N- and T-type calcium channels Pain 2019 160 1 117 135 10.1097/j.pain.0000000000001385 2-s2.0-85059172506 30169422 323 Kalra J. Lingaraju M. C. Mathesh K. Betulinic acid alleviates dextran sulfate sodium-induced colitis and visceral pain in mice Naunyn-Schmiedeberg’s Archives of Pharmacology 2018 391 3 285 297 10.1007/s00210-017-1455-3 2-s2.0-85039072461 324 Oyebanji B. O. Saba A. B. Oridupa O. A. Studies on the anti-inflammatory, analgesic and antipyrexic activities of betulinic acid derived from Tetracera potatoria African journal of Traditional, Complementary, and Alternative Medicines 2014 11 1 30 33 325 Rios J. L. Manez S. New pharmacological opportunities for betulinic acid Planta Medica 2018 84 1 8 19 10.1055/s-0043-123472 2-s2.0-85038637058 29202513 326 Yogeeswari P. Sriram D. Betulinic acid and its derivatives: a review on their biological properties Current Medicinal Chemistry 2005 12 6 657 666 10.2174/0929867053202214 2-s2.0-14744293458 15790304 327 Borghi S. M. Pinho-Ribeiro F. A. Fattori V. Quercetin inhibits peripheral and spinal cord nociceptive mechanisms to reduce intense acute swimming-induced muscle pain in mice PLoS One 2016 11 9 e0162267 10.1371/journal.pone.0162267 2-s2.0-84991010117 328 Calixto-Campos C. Correa M. P. Carvalho T. T. Quercetin reduces Ehrlich tumor-induced cancer pain in mice Analytical Cellular Pathology (Amsterdam) 2015 2015 285708 10.1155/2015/285708 2-s2.0-84940481067 329 Carullo G. Cappello A. R. Frattaruolo L. Badolato M. Armentano B. Aiello F. Quercetin and derivatives: useful tools in inflammation and pain management Future Medicinal Chemistry 2017 9 1 79 93 10.4155/fmc-2016-0186 2-s2.0-85008144018 27995808 330 Filho A. W. Filho V. C. Olinger L. de Souza M. M. Quercetin: further investigation of its antinociceptive properties and mechanisms of action Archives of Pharmacal Research 2008 31 6 713 721 10.1007/s12272-001-1217-2 2-s2.0-45749089003 18563352 331 Li Z. Zhang J. Ren X. Liu Q. Yang X. The mechanism of quercetin in regulating osteoclast activation and the PAR2/TRPV1 signaling pathway in the treatment of bone cancer pain International Journal of Clinical and Experimental Pathology 2018 11 11 5149 5156 31949595 332 Martinez A. L. Gonzalez-Trujano M. E. Aguirre-Hernandez E. Moreno J. Soto-Hernandez M. Lopez-Munoz F. J. Antinociceptive activity of Tilia americana var. Mexicana inflorescences and quercetin in the formalin test and in an arthritic pain model in rats Neuropharmacology 2009 56 2 564 571 10.1016/j.neuropharm.2008.10.010 2-s2.0-58849084063 19027760 333 Shoskes D. A. Nickel J. C. Quercetin for chronic prostatitis/chronic pelvic pain syndrome Urologic Clinics of North America 2011 38 3 279 284 10.1016/j.ucl.2011.05.003 2-s2.0-79960623420 334 Valerio D. A. Georgetti S. R. Magro D. A. Quercetin reduces inflammatory pain: inhibition of oxidative stress and cytokine production Journal of Natural Products 2009 72 11 1975 1979 10.1021/np900259y 2-s2.0-73349137314 19899776 335 Anjaneyulu M. Chopra K. Quercetin, a bioflavonoid, attenuates thermal hyperalgesia in a mouse model of diabetic neuropathic pain Prog Neuropsychopharmacol Biol Psychiatry 2003 27 6 1001 1005 10.1016/s0278-5846(03)00160-x 2-s2.0-0141851856 14499317 336 Anjaneyulu M. Chopra K. Quercetin attenuates thermal hyperalgesia and cold allodynia in STZ-induced diabetic rats Indian Journal of Experimental Biology 2004 42 8 766 769 15573524 337 Azevedo M. I. Pereira A. F. Nogueira R. B. The antioxidant effects of the flavonoids rutin and quercetin inhibit oxaliplatin-induced chronic painful peripheral neuropathy Molecular Pain 2013 9 p. 53 10.1186/1744-8069-9-53 2-s2.0-84886006088 24152430 338 Dureshahwar K. Mubashir M. Une H. D. Quantification of quercetin obtained from Allium cepa Lam. leaves and its effects on streptozotocin-induced diabetic neuropathy Pharmacognosy Research 2017 9 3 287 293 10.25258/phyto.v9i5.8157 28827972 339 Ferreira P. E. Lopes C. R. Alves A. M. Diabetic neuropathy: an evaluation of the use of quercetin in the cecum of rats World Journal of Gastroenterology 2013 19 38 6416 6426 10.3748/wjg.v19.i38.6416 2-s2.0-84885646002 24151360 340 Gao W. Zan Y. Wang Z. J. Hu X. Y. Huang F. Quercetin ameliorates paclitaxel-induced neuropathic pain by stabilizing mast cells, and subsequently blocking PKCε -dependent activation of TRPV1 Acta Pharmacologica Sinica 2016 37 9 1166 1177 10.1038/aps.2016.58 2-s2.0-84984905382 27498772 341 Ji C. Xu Y. Han F. Quercetin alleviates thermal and cold hyperalgesia in a rat neuropathic pain model by inhibiting Toll-like receptor signaling Biomedicine & Pharmacotherapy 2017 94 652 658 10.1016/j.biopha.2017.07.145 2-s2.0-85026777332 28787700 342 Muto N. Matsuoka Y. Arakawa K. Quercetin attenuates neuropathic pain in rats with spared nerve injury Acta Medica Okayama 2018 72 5 457 465 10.18926/AMO/56243 30369602 343 Naidu P. S. Singh A. Kulkarni S. K. D2-dopamine receptor and alpha2-adrenoreceptor-mediated analgesic response of quercetin Indian Journal of Experimental Biology 2003 41 12 1400 1404 15320492 344 Raygude K. S. Kandhare A. D. Ghosh P. Ghule A. E. Bodhankar S. L. Evaluation of ameliorative effect of quercetin in experimental model of alcoholic neuropathy in rats Inflammopharmacology 2012 20 6 331 341 10.1007/s10787-012-0122-z 2-s2.0-84872162529 22349996 345 Xie J. Song W. Liang X. Protective effect of quercetin on streptozotocin-induced diabetic peripheral neuropathy rats through modulating gut microbiota and reactive oxygen species level Biomedicine & Pharmacotherapy 2020 127 110147 10.1016/j.biopha.2020.110147 346 Yang R. Li L. Yuan H. Quercetin relieved diabetic neuropathic pain by inhibiting upregulated P2X4 receptor in dorsal root ganglia Journal of Cellular Physiology 2019 234 3 2756 2764 10.1002/jcp.27091 2-s2.0-85052469366 30145789 347 Kandhare A. D. Raygude K. S. Kumar V. S. Ameliorative effects quercetin against impaired motor nerve function, inflammatory mediators and apoptosis in neonatal streptozotocin-induced diabetic neuropathy in rats Biomedicine and Aging Pathology 2012 2 4 173 186 10.1016/j.biomag.2012.10.002 2-s2.0-84871387375 348 Acikara O. B. Citoglu G. S. Dall’Acqua S. Bioassay-guided isolation of the antinociceptive compounds motiol and beta-sitosterol from Scorzonera latifolia root extract Pharmazie 2014 69 9 711 714 25272946 349 Das N. Bhattacharya A. Kumar Mandal S. Ichnocarpus frutescens (L.) R. Br. root derived phyto-steroids defends inflammation and algesia by pulling down the pro-inflammatory and nociceptive pain mediators: an in-vitro and in-vivo appraisal Steroids 2018 139 18 27 10.1016/j.steroids.2018.09.005 2-s2.0-85053811763 30217788 350 Hernandez-Flores M. E. Torres-Valencia J. M. Carino-Cortes R. In search of safe pain relief: the analgesic and anti-inflammatory activity of phytosteryl ibuprofenates Steroids 2019 149 108420 10.1016/j.steroids.2019.05.012 2-s2.0-85067518315 351 Nirmal S. A. Pal S. C. Mandal S. C. Patil A. N. Analgesic and anti-inflammatory activity of beta-sitosterol isolated from Nyctanthes arbortristis leaves Inflammopharmacology 2012 20 4 219 224 10.1007/s10787-011-0110-8 2-s2.0-84864949899 22207496 352 Paniagua-Perez R. Flores-Mondragon G. Reyes-Legorreta C. Evaluation of the anti-inflammatory capacity of beta-sitosterol in rodent assays African Journal of Traditional, Complementary, and Alternative Medicines 2017 14 1 123 130 10.21010/ajtcam.v14i1.13 2-s2.0-85021858951 353 Santos A. R. Niero R. Filho V. C. Antinociceptive properties of steroids isolated from Phyllanthus corcovadensis in mice Planta Medica 1995 61 4 329 332 10.1055/s-2006-958093 2-s2.0-0029142463 7480179 354 Battisti W. P. Katz N. P. Weaver A. L. Pain management in osteoarthritis: a focus on onset of efficacy—a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials Journal of Pain 2004 5 9 511 520 10.1016/j.jpain.2004.09.004 2-s2.0-8844270064